Data / Research funding / Colo-Rectal Cancer
Colo-Rectal Cancer: 512 NIH awards ($373.9M) to 182 organizations
512 NIH awards ($373.9M) in the NIH spending category Colo-Rectal Cancer, to 182 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 512 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| UT Southwestern Medical Center Simmons Comprehensive Cancer Center | NIH | National Cancer Institute | 2021 to 2025 | $21,900,548 | September 1, 2010 | July 31, 2026 | ARTEAGA, CARLOS L | reporter.nih.gov |
| Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $19,528,719 | June 1, 1997 | June 30, 2028 | STEIDL, ULRICH | reporter.nih.gov |
| Administrative Supplement for the NCI P30 CCSG to extend partnerships with comprehensive cancer control coalitions to study implementation of evidence-based cancer control interventions | NIH | National Cancer Institute | 2021 | $11,079,774 | January 1, 1997 | March 31, 2022 | LYNCH, THOMAS JAMES | reporter.nih.gov |
| Statistical Methods for Integrative Genomics in Cancer | NIH | National Cancer Institute | 2021 to 2025 | $8,721,062 | July 1, 2016 | August 31, 2027 | GAUDERMAN, WILLIAM JAMES | reporter.nih.gov |
| Base Title: PREVENT Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint BiomarkersTask Order Title: Colorectal Cancer (CRC) Prevention by TPST-1495 in PIRC rat mod | NIH | National Cancer Institute | 2021 to 2023 | $7,628,615 | September 11, 2023 | September 10, 2026 | RAO, CHINTHALAPALLY | reporter.nih.gov |
| The Cleveland Digestive Diseases Research Core Center (DDRCC) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $6,425,666 | February 15, 2015 | August 31, 2030 | COMINELLI, FABIO | reporter.nih.gov |
| Optimizing Colorectal Cancer Screening PREcision and Outcomes in CommunIty-baSEd Populations (PRECISE) | NIH | National Cancer Institute | 2021 to 2023 | $6,108,355 | April 15, 2018 | March 31, 2025 | CORLEY, DOUGLAS ALLEN | reporter.nih.gov |
| CRC-HUB-SPOKE: A ColoRectal Cancer screening Hub for Southern California community health centers. | NIH | National Cancer Institute | 2021 to 2023 | $4,080,149 | September 19, 2019 | August 31, 2025 | MARTINEZ, MARIA ELENA | reporter.nih.gov |
| Smarter CRC Supplement for ACCSIS Patient Navigation | NIH | National Cancer Institute | 2021 to 2023 | $3,328,541 | September 23, 2019 | August 31, 2025 | DAVIS, MELINDA MARIE | reporter.nih.gov |
| Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and Treatment | NIH | National Cancer Institute | 2021 to 2023 | $2,814,960 | December 29, 2016 | November 30, 2023 | MARKOWITZ, SANFORD D. | reporter.nih.gov |
| ACCISIS-Chicago | NIH | National Cancer Institute | 2021 to 2022 | $2,329,000 | September 21, 2018 | August 31, 2023 | KIM, KAREN E | reporter.nih.gov |
| PCPT and SELECT Cohorts: Core Infrastructure Support for Cancer Research | NIH | National Cancer Institute | 2021 to 2023 | $2,327,659 | September 20, 2013 | July 31, 2025 | TANGEN, CATHERINE M. | reporter.nih.gov |
| (ACCSIS) Accelerating Colorectal Cancer Screening through Implementation Science in Appalachia | NIH | National Cancer Institute | 2021 to 2022 | $2,310,722 | September 19, 2018 | March 31, 2025 | DIGNAN, MARK B | reporter.nih.gov |
| Development and Validation of Prognostic Radiomic Markers of Response and Recurrence for Patients with Colorectal Liver Metastases | NIH | National Cancer Institute | 2021 to 2023 | $2,284,583 | March 1, 2019 | August 31, 2025 | DO, RICHARD KINH GIAN | reporter.nih.gov |
| Scaling Colorectal Cancer Screening Through Outreach, Referral, and Engagement (SCORE): A State-Level Program to Reduce Colorectal Cancer Burden in Vulnerable Populations | NIH | National Cancer Institute | 2021 to 2023 | $2,126,299 | September 30, 2018 | August 31, 2024 | REULAND, DANIEL S. | reporter.nih.gov |
| Reverse transcriptase inhibitor effects on the mobilome of colon cancer | NIH | National Cancer Institute | 2021 to 2023 | $2,117,061 | July 1, 2019 | June 30, 2025 | TING, DAVID TSAI | reporter.nih.gov |
| Uncovering exRNA and protein determinants of secreted vesicle heterogeneity by flow cytometric purification of vesicle subsets from cells and plasma | NIH | National Cancer Institute | 2021 to 2022 | $2,099,368 | July 15, 2019 | August 31, 2024 | COFFEY, ROBERT J. | reporter.nih.gov |
| Treg-depleting immunotherapy | NIH | National Cancer Institute | 2021 to 2022 | $2,000,000 | September 7, 2020 | September 30, 2024 | SUZDAK, PETER DAVID | reporter.nih.gov |
| Robust Predictor of Colon Cancer Risk | NIH | National Cancer Institute | 2022 to 2023 | $1,999,992 | September 13, 2018 | July 31, 2025 | OSTRER, HARRY | reporter.nih.gov |
| Development of SUMO1 small molecule degraders as the first-in-class anticancerdrugs for metastatic colorectal cancer | NIH | National Cancer Institute | 2022 to 2023 | $1,999,119 | July 1, 2022 | June 30, 2025 | BELLAIL, ANITA | reporter.nih.gov |
| Cancer Registry for Understanding and Improving Survivorship Experiences (CRUISE) | NIH | National Cancer Institute | 2021 to 2023 | $1,936,037 | June 10, 2019 | May 31, 2025 | SARKAR, URMIMALA | reporter.nih.gov |
| Disparities in access to and outcomes of cancer surgery for rural Medicare patients | NIH | National Cancer Institute | 2021 to 2023 | $1,929,880 | March 1, 2020 | February 28, 2025 | TOSTESON, ANNA N. A. | reporter.nih.gov |
| Ultra-high content analyses of circulating and solid tumor cells: A diagnostic reference system for disease burden | NIH | National Cancer Institute | 2021 to 2023 | $1,913,568 | August 16, 2021 | August 31, 2025 | NEDERLOF, MICHEL | reporter.nih.gov |
| Metabolomic Strategies for Discovery and Validation of Biomarkers of Colorectal Cancer Recurrence | NIH | National Cancer Institute | 2021 to 2022 | $1,902,826 | April 1, 2017 | March 31, 2024 | ULRICH, CORNELIA M | reporter.nih.gov |
| Transcriptome-wide association study to identify susceptibility genes for colorectal cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,901,832 | September 4, 2018 | August 31, 2025 | GUO, XINGYI | reporter.nih.gov |
| Biology of R-Spondin-Induced Sensitization to Asparaginase in Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,889,937 | August 1, 2021 | July 21, 2024 | GUTIERREZ, ALEJANDRO | reporter.nih.gov |
| Nano-Engineered Lab-on-a-Chip for Assessing HuR-Regulated Exosomes for Cancer Monitoring and Targeted Therapy | NIH | National Cancer Institute | 2021 to 2023 | $1,832,571 | May 16, 2019 | April 30, 2026 | XU, LIANG | reporter.nih.gov |
| Development and Validation of a Measure of Organizational Readiness (motivation x capacity) for Implementation | NIH | National Cancer Institute | 2021 to 2023 | $1,817,941 | December 1, 2018 | November 30, 2025 | FERNANDEZ, MARIA EULALIA | reporter.nih.gov |
| The Impact of Circadian Misalignment on Colonic Barrier Homeostasis in Ulcerative Colitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,790,331 | February 1, 2021 | June 4, 2023 | SWANSON, GARTH R | reporter.nih.gov |
| The immune contexture of colorectal adenomas and serrated polyps | NIH | National Cancer Institute | 2021 to 2023 | $1,762,921 | September 1, 2020 | August 31, 2025 | WALLACE, KRISTIN | reporter.nih.gov |
| Microsystems imaging system for epithelial-derived cancer heterogeneity | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2023 | $1,730,519 | September 1, 2019 | May 31, 2025 | WANG, THOMAS D | reporter.nih.gov |
| A Noninvasive Integrated Genomic Approach for Early Cancer Detection and Risk Stratification after Transplantation | NIH | National Cancer Institute | 2021 to 2023 | $1,728,199 | March 1, 2019 | February 29, 2024 | KHUSH, KIRAN KAUR | reporter.nih.gov |
| Discovery of Small Molecule Ligands for PHD1 Reader Domain of Histone Demethylase KDM5A | NIH | National Cancer Institute | 2021 to 2023 | $1,722,094 | July 1, 2020 | June 30, 2024 | FUJIMORI, DANICA GALONIC | reporter.nih.gov |
| Culturally Adapted Multilevel Decision Support Navigation Trial to Reduce Colorectal Cancer Disparity among At-Risk Asian American Primary Care Patients | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2022 | $1,695,812 | September 26, 2017 | December 31, 2025 | LEE, SUNMIN | reporter.nih.gov |
| Molecular basis for dietary chemoprevention | NIH | National Cancer Institute | 2021 to 2022 | $1,628,302 | March 1, 2016 | February 28, 2023 | CHAPKIN, ROBERT STEPHEN | reporter.nih.gov |
| DNA Methyltransferase Gene Expression in Colon Cancer | NIH | National Institute of Environmental Health Sciences | 2021 to 2023 | $1,625,091 | April 1, 1991 | February 28, 2025 | BAYLIN, STEPHEN B. | reporter.nih.gov |
| The NYU Women's Health Study | NIH | National Cancer Institute | 2021 to 2023 | $1,621,115 | May 1, 2015 | April 30, 2025 | CHEN, YU | reporter.nih.gov |
| Immunoprevention and immunosurveillance of human non-viral cancers | NIH | National Cancer Institute | 2021 to 2022 | $1,608,806 | August 1, 2016 | July 31, 2023 | FINN, OLIVERA J | reporter.nih.gov |
| Three-Dimensional Multi-Parametric Ultrasound for Monitoring Therapy of Liver Metastasis | NIH | National Cancer Institute | 2021 to 2023 | $1,604,984 | April 1, 2016 | February 29, 2024 | EL KAFFAS, AHMED | reporter.nih.gov |
| The miR-20/c-Myc/E2F Regulatory Axis is Critical for the Tumor Promoting Activity of Inflammatory Fibroblasts in Colitis-Associated Cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,582,909 | March 1, 2019 | August 31, 2025 | HUANG, EMINA HUI-NA | reporter.nih.gov |
| Post-polypectomy Surveillance for Reducing Colon Cancer Incidence and Mortality | NIH | National Cancer Institute | 2021 to 2023 | $1,569,749 | February 1, 2018 | December 31, 2024 | GUPTA, SAMIR | reporter.nih.gov |
| SMAD4 regulation of colon epithelial cell inflammatory responses | NIH | National Cancer Institute | 2021 to 2023 | $1,533,094 | July 1, 2019 | June 30, 2024 | MEANS, ANNA L | reporter.nih.gov |
| Exosomal Biomarkers for the Noninvasive Detection of Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,510,680 | August 20, 2019 | July 31, 2025 | GOEL, AJAY | reporter.nih.gov |
| SurvivorCare: A digital health solution to support long-term cancer survivorship using patient navigation | NIH | National Cancer Institute | 2021 to 2022 | $1,501,567 | September 21, 2021 | August 31, 2024 | HO, Y. XIAN | reporter.nih.gov |
| Point of care, real-time urine metabolomics test to diagnose colorectal cancers and polyps in low- and middle-income countries | NIH | National Cancer Institute | 2021 to 2022 | $1,491,465 | April 15, 2017 | April 30, 2024 | KINGHAM, T PETER | reporter.nih.gov |
| Coordinating Center for Population-based Research to Optimize Cancer Screening (PROSPR) (U24) | NIH | National Cancer Institute | 2022 to 2023 | $1,464,869 | April 15, 2018 | March 31, 2026 | LI, CHRISTOPHER I | reporter.nih.gov |
| Neoantigen Vaccination for Lynch Syndrome Immunoprevention | NIH | National Cancer Institute | 2021 to 2022 | $1,418,370 | September 30, 2018 | August 31, 2024 | LIPKIN, STEVEN M | reporter.nih.gov |
| Prediciting and addressing colonoscopy non-adherence in community settings | NIH | National Cancer Institute | 2021 to 2022 | $1,403,333 | April 1, 2018 | March 31, 2024 | CORONADO, GLORIA D | reporter.nih.gov |
| Drug-Loaded Nanobubbles for Ultrasound Enhanced Delivery to Colon Cancer Liver Metastasis | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2023 | $1,397,305 | September 30, 2019 | June 30, 2025 | EXNER, AGATA A | reporter.nih.gov |
| A Fragment-Based Strategy for K-RAS Covalent Inhibitors | NIH | National Cancer Institute | 2021 to 2023 | $1,388,881 | July 2, 2021 | March 1, 2024 | MEROUEH, SAMY | reporter.nih.gov |
| Determining the risk factor profile and biology of colorectal cancer in Nigeria | NIH | National Cancer Institute | 2021 to 2023 | $1,386,615 | August 1, 2020 | April 30, 2025 | KINGHAM, T PETER | reporter.nih.gov |
| Addressing the Biology of Health Disparities by Targeting Geographical Ancestry-driven Variants of Immunity | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2022 | $1,381,253 | September 20, 2021 | July 7, 2023 | KIMBRO, KEVIN SEAN | reporter.nih.gov |
| A Chemical Genetic Approach to Exploring Novel Therapeutic Space for Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,377,857 | March 1, 2021 | May 31, 2023 | DAR, ARVIN | reporter.nih.gov |
| Tissue-specific genetic interactions in cancer | NIH | National Cancer Institute | 2021 to 2022 | $1,375,018 | June 20, 2018 | May 31, 2024 | HAIGIS, KEVIN | reporter.nih.gov |
| Preclinical validation of oral therapeutic lead proteins targeting epithelial GM1 ganglioside for ulcerative colitis therapy | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,370,301 | June 20, 2020 | March 31, 2026 | MATOBA, NOBUYUKI | reporter.nih.gov |
| KanSurvive: Testing a model for improving cancer survivorship care in rural practice | NIH | National Cancer Institute | 2021 to 2023 | $1,358,381 | August 23, 2019 | July 31, 2025 | KLEMP, JENNIFER ROSE | reporter.nih.gov |
| Microbiome-triggered reprogramming and mutation of colon epithelial cells leading to tumor stem-like cells | NIH | National Cancer Institute | 2021 to 2023 | $1,358,184 | April 1, 2019 | March 31, 2025 | HUYCKE, MARK M | reporter.nih.gov |
| Self-immolative prodrug/miRNA nanoparticle combinations for cancer treatment | NIH | National Cancer Institute | 2021 to 2023 | $1,351,610 | February 11, 2019 | January 31, 2026 | OUPICKY, DAVID | reporter.nih.gov |
| MDACC-PREDICT | NIH | National Cancer Institute | 2021 to 2022 | $1,327,977 | September 1, 2020 | August 31, 2025 | MANNING, HENRY CHARLES | reporter.nih.gov |
| Longitudinal therapeutic monitoring of colorectal cancer patients using exosome-based liquid biopsies | NIH | National Cancer Institute | 2021 to 2022 | $1,314,717 | July 1, 2018 | June 30, 2024 | MAITRA, ANIRBAN | reporter.nih.gov |
| Promoting follow-up of abnormal cancer screening tests using population-basedsystems to support stepped care multilevel intervention | NIH | National Cancer Institute | 2021 to 2022 | $1,305,011 | September 30, 2018 | August 31, 2024 | HAAS, JENNIFER S | reporter.nih.gov |
| Integrated Acoustofluidic Plasmonic Molecular Diagnostic System for Detecting MicroRNA Biomarkers | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $1,295,118 | January 1, 2020 | December 31, 2025 | VO-DINH, TUAN | reporter.nih.gov |
| Ultrabright Theranostic SERRS Nanoparticles for Gastrointestinal Endoscopy | NIH | National Cancer Institute | 2022 to 2023 | $1,275,697 | February 1, 2018 | May 31, 2025 | ROGALLA, STEPHAN | reporter.nih.gov |
| SREBP-Mediated Regulation of Intestinal Epithelial Homeostasis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,268,460 | August 1, 2019 | May 31, 2025 | ENGELKING, LUKE JAMES | reporter.nih.gov |
| LFA-9 (mPGES-1/5-LOX Inhibitor): Preclinical Studies to Support a Clinical Trial, | NIH | National Cancer Institute | 2021 to 2023 | $1,262,892 | September 17, 2018 | March 16, 2024 | MCCORMICK, DAVID | reporter.nih.gov |
| Role of tumor microenvironment-derived cholesterol in CD8+ T-cell exhaustion | NIH | National Cancer Institute | 2021 to 2023 | $1,259,518 | August 1, 2019 | July 31, 2025 | YI, QING | reporter.nih.gov |
| Integrative Single-Cell Atlas of Host and Microenvironment in Colorectal Neoplastic Transformation | NIH | National Cancer Institute | 2021 to 2023 | $1,252,480 | May 1, 2023 | August 31, 2024 | COFFEY, ROBERT J. | reporter.nih.gov |
| Microvasculature in Colon Field Carcinogenesis: Clinical-Biological Implications | NIH | National Cancer Institute | 2021 to 2022 | $1,244,763 | March 5, 2018 | February 28, 2025 | ROY, HEMANT K. | reporter.nih.gov |
| Three dimensional nanoscale nuclear architecture mapping based taxonomy of precursor lesions for predicting colorectal cancer risk | NIH | National Cancer Institute | 2021 to 2023 | $1,240,003 | April 1, 2019 | March 31, 2025 | UTTAM, SHIKHAR | reporter.nih.gov |
| Reducing Cancer Transcriptional Heterogeneity through Regulation of Chromatin Structure | NIH | National Cancer Institute | 2021 to 2022 | $1,239,236 | April 9, 2018 | March 31, 2025 | BACKMAN, VADIM | reporter.nih.gov |
| Bacterial correlates of colorectal cancer subgroups and survival | NIH | National Cancer Institute | 2021 to 2022 | $1,231,902 | September 1, 2018 | August 31, 2025 | PHIPPS, AMANDA IRENE | reporter.nih.gov |
| Investigating Amino Acid Depletion in the Tumor Microenvironment as a Metabolic Immune Checkpoint | NIH | National Cancer Institute | 2021 to 2023 | $1,229,239 | December 2, 2020 | November 30, 2023 | THOMPSON, CRAIG B | reporter.nih.gov |
| Rational translation of gold nanoparticle mediated radiosensitization tothe clinic | NIH | National Cancer Institute | 2021 to 2022 | $1,222,438 | January 13, 2021 | September 5, 2022 | KRISHNAN, SUNIL | reporter.nih.gov |
| Genetic and Dietary Interactions in MMR Deficient Colon Tumorigenesis | NIH | National Cancer Institute | 2021 to 2022 | $1,203,660 | July 5, 2018 | May 31, 2024 | AUGENLICHT, LEONARD H | reporter.nih.gov |
| Statistical Methods for Analysis of Tumor Heterogeneity in Genetic Epidemiology | NIH | National Cancer Institute | 2021 to 2023 | $1,166,626 | July 1, 2015 | June 30, 2025 | HSU, LI | reporter.nih.gov |
| Elucidating the Role of MALAT1 Somatic Driver Mutations in Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,147,685 | December 4, 2018 | November 30, 2024 | LIPKIN, STEVEN M | reporter.nih.gov |
| Epigenomic Reprogramming in Patient Derived Models of Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2022 | $1,141,487 | September 1, 2018 | August 31, 2024 | HSU, SHIAOWEN DAVID | reporter.nih.gov |
| D3-creatine dilution to determine skeletal muscle mass in colon cancer patients | NIH | National Cancer Institute | 2021 to 2023 | $1,136,772 | February 1, 2020 | January 31, 2025 | FELICIANO, ELIZABETH MARJORIE CESPEDES | reporter.nih.gov |
| Role of the microbiota in DNA methylation and CRC development | NIH | National Cancer Institute | 2021 to 2022 | $1,135,049 | December 15, 2017 | November 30, 2023 | ISSA, JEAN-PIERRE J. | reporter.nih.gov |
| Detection of somatic, subclonal and mosaic CNVs from sequencing | NIH | National Cancer Institute | 2021 to 2022 | $1,134,197 | May 1, 2018 | April 30, 2024 | ABYZOV, ALEXEJ | reporter.nih.gov |
| Carbohydrate Structure Controls on Human Gut Microbial Ecology | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $1,127,763 | August 9, 2019 | June 30, 2025 | LINDEMANN, STEPHEN ROBERT | reporter.nih.gov |
| Development and Mechanistic Studies of an Engineered Human Enzyme to Abrogate Immune Suppression due to Elevated Methylthioadenosine (MTA) by MTAP null/low Tumors | NIH | National Cancer Institute | 2021 to 2023 | $1,119,912 | July 1, 2019 | June 30, 2025 | STONE, EVERETT | reporter.nih.gov |
| A Case-Control Study to Evaluate Broad-Spectrum Antibiotic use and High Birth Weight as Potential Risk Factors for Early-Onset Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,102,454 | September 15, 2021 | August 31, 2025 | CHAO, CHUN R. | reporter.nih.gov |
| CXCR4 as a target for colon cancer chemoprevention | NIH | National Cancer Institute | 2021 to 2023 | $1,083,245 | July 1, 2019 | June 30, 2024 | BISSONNETTE, BRUCE MARC | reporter.nih.gov |
| CCAR2 as a Target for Prevention of Colorectal Cancer. | NIH | National Cancer Institute | 2021 to 2023 | $1,080,815 | April 1, 2008 | February 28, 2025 | DASHWOOD, RODERICK H | reporter.nih.gov |
| Regulation of Necroptosis and inflammation | NIH | National Cancer Institute | 2021 to 2023 | $1,076,589 | January 1, 2019 | December 31, 2023 | LOU, ZHENKUN | reporter.nih.gov |
| Enhancing Prevention Pathways Towards Tribal Colorectal Health | NIH | National Cancer Institute | 2021 to 2022 | $1,073,429 | April 1, 2016 | June 30, 2024 | MISHRA, SHIRAZ I. | reporter.nih.gov |
| DOTA-based pre-targeting of alpha emitters | NIH | National Cancer Institute | 2022 to 2023 | $1,071,344 | December 10, 2018 | November 30, 2024 | CHEAL, SARAH MARIE | reporter.nih.gov |
| Defining Mechanisms of Transformation Driven By the Zinc Finger Transcription Factor PLAGL2 in the Intestinal Epithelium | NIH | National Cancer Institute | 2021 to 2023 | $1,066,433 | April 1, 2019 | March 31, 2025 | RUBIN, DEBORAH C. | reporter.nih.gov |
| Wnt Signaling in intestinal stem cells, homeostasis, and cancer | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $1,042,786 | August 20, 2019 | May 31, 2024 | HE, XI | reporter.nih.gov |
| SUPPORT SERVICES FOR THE PLCO ETIOLOGIC&EARLY MARKER STUDIES (PLCO EEMS) | NIH | National Cancer Institute | 2021 | $1,024,263 | July 20, 2020 | July 19, 2021 | RILEY, THOMAS | reporter.nih.gov |
| Mechanisms and Correction of Abnormal Bicarbonate Secretion by DRA in Diarrhea | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $1,021,334 | February 5, 2019 | May 31, 2024 | TSE, CHUNG-MING | reporter.nih.gov |
| DKK2 regulates NK activation and tumor immunity | NIH | National Cancer Institute | 2021 to 2022 | $1,016,358 | December 1, 2017 | December 31, 2023 | WU, DIANQING | reporter.nih.gov |
| Early Prediction of Tumor Response to Treatment: Clinical Translation of [99mTc]-Duramycin | NIH | National Cancer Institute | 2021 to 2022 | $1,015,350 | February 1, 2019 | January 31, 2025 | PAK, KOON Y | reporter.nih.gov |
| The function of lysophosphatidic acid receptor LPA5R in intestinal inflammation and epithelial damage | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $1,014,004 | September 20, 2018 | May 31, 2024 | YUN, CHANGHYON CHRIS | reporter.nih.gov |
| Illuminating the evolutionary history of colorectal cancer metastasis: basic principles and clinical applic | NIH | National Cancer Institute | 2021 to 2023 | $1,005,583 | June 1, 2023 | August 31, 2023 | NAXEROVA, KAMILA | reporter.nih.gov |
| Active Disposable Cap for Endoscope Tip Stabilization and Complete Visualization and Dissection of Serrated Sessile Polyps | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $999,979 | August 7, 2018 | December 31, 2022 | MULVIHILL, MAUREEN L. | reporter.nih.gov |
| Imaging nanoscale chromatin folding in early carcinogenesis | NIH | National Cancer Institute | 2021 to 2023 | $996,716 | August 1, 2020 | December 31, 2023 | LIU, YANG | reporter.nih.gov |
| Controllable In Vivo Genome Editing for Immune-Checkpoint Blockade in Solid Tumors | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2022 | $989,015 | August 21, 2018 | May 31, 2024 | TONG, SHENG | reporter.nih.gov |
| Nutritionally Driven Sporadic Intestinal Tumors: Impact on Stem Cells | NIH | National Cancer Institute | 2021 to 2022 | $976,612 | July 5, 2018 | May 31, 2024 | AUGENLICHT, LEONARD H | reporter.nih.gov |
| The role of Interleukin 17RB signaling in colorectal cancer progression | NIH | National Cancer Institute | 2021 to 2022 | $947,522 | July 1, 2021 | June 30, 2023 | GRIVENNIKOV, SERGEI I | reporter.nih.gov |
| Accelerating Transdisciplinary Epidemiology of Colorectal Cancer | NIH | National Cancer Institute | 2021 | $931,108 | August 1, 2019 | July 31, 2022 | OGINO, SHUJI | reporter.nih.gov |
| Translation addiction and targeting in colon cancer | NIH | National Cancer Institute | 2021 to 2022 | $928,987 | January 1, 2018 | March 31, 2023 | YU, JIAN | reporter.nih.gov |
| Combined NGS tumor-based detection of germline Lynch syndrome mutations and prognostic classification of endometrial cancers | NIH | National Cancer Institute | 2021 to 2022 | $925,110 | July 6, 2018 | June 30, 2024 | GOODFELLOW, PAUL JOSEPH | reporter.nih.gov |
| DOTA-based pre-targeting of alpha emitters | NIH | National Cancer Institute | 2021 to 2022 | $918,123 | December 10, 2018 | December 31, 2021 | CHEAL, SARAH MARIE | reporter.nih.gov |
| Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer | NIH | National Cancer Institute | 2021 to 2022 | $917,725 | September 13, 2018 | August 31, 2024 | FINLEY, STACEY DELERIA | reporter.nih.gov |
| Mechanisms of cytokine driven tumor elicited inflammation in colorectal cancer | NIH | National Cancer Institute | 2021 to 2022 | $912,962 | September 1, 2020 | August 31, 2024 | GRIVENNIKOV, SERGEI I | reporter.nih.gov |
| (PQ1) Adaptive immune and microbial mechanisms regulating Lynch syndrome penetrance | NIH | National Cancer Institute | 2021 to 2022 | $911,675 | September 4, 2018 | August 31, 2024 | LIPKIN, STEVEN M | reporter.nih.gov |
| Development and validation of clinical prediction models for the use and interpretation of multigene hereditary cancer risk assessment | NIH | National Cancer Institute | 2021 to 2022 | $901,778 | September 30, 2008 | January 31, 2025 | SYNGAL, SAPNA | reporter.nih.gov |
| Metabolic regulation of intestinal stem cell homeostasis | NIH | National Cancer Institute | 2021 to 2022 | $900,942 | July 1, 2018 | June 30, 2024 | RUTTER, JARED P | reporter.nih.gov |
| Early life exposures and risk of young-onset colorectal cancer | NIH | National Cancer Institute | 2021 to 2023 | $892,717 | September 1, 2021 | August 31, 2025 | MURPHY, CAITLIN C | reporter.nih.gov |
| Gain-of-function mutant p53 and metabolic reprogramming in colorectal cancer | NIH | National Cancer Institute | 2021 to 2022 | $890,528 | April 1, 2021 | March 31, 2023 | HU, WENWEI | reporter.nih.gov |
| Theory and methods for mediation and interaction | NIH | National Cancer Institute | 2021 to 2022 | $885,392 | February 19, 2018 | January 31, 2025 | VANDERWEELE, TYLER | reporter.nih.gov |
| Role of necroptosis in colorectal cancer therapy | NIH | National Cancer Institute | 2021 to 2022 | $882,531 | June 1, 2019 | May 31, 2023 | ZHANG, LIN | reporter.nih.gov |
| Liver Cancer Therapy by MiR-22 and Its Inducers | NIH | National Cancer Institute | 2021 to 2023 | $876,644 | February 1, 2018 | January 31, 2025 | WAN, YU-JUI YVONNE | reporter.nih.gov |
| A microengineered colon cancer-chip designed to investigate tumor-stromal interactions driving cancer progression | NIH | National Cancer Institute | 2021 | $875,151 | December 1, 2020 | November 30, 2021 | MUMENTHALER, SHANNON MICHELLE | reporter.nih.gov |
| Targeting defective necroptosis in colorectal cancer | NIH | National Cancer Institute | 2021 to 2022 | $874,071 | December 1, 2019 | November 30, 2024 | ZHANG, LIN | reporter.nih.gov |
| Using Natural Language Processing and Crowdsourcing to Monitor and Evaluate Public Information and Communication Disparities about Colon Cancer Screening | NIH | National Cancer Institute | 2021 to 2022 | $867,795 | April 15, 2021 | June 30, 2022 | KING, ANDY J | reporter.nih.gov |
| The role of cell-specific TLR-4 signaling in oxaliplatin-induced peripheral neuropathy | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $864,952 | September 15, 2018 | June 30, 2025 | WHITE, FLETCHER A | reporter.nih.gov |
| Development of a Dual and Selective Small Molecule Inhibitor of EGFR and PI3 Kinase to Treat BRAF Mutant Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2022 | $863,904 | April 17, 2018 | March 31, 2024 | LEOPOLD, JUDITH S | reporter.nih.gov |
| Massively parallel experimental measurement of variant functional impacts | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $861,644 | August 6, 2018 | May 31, 2024 | KITZMAN, JACOB OTTO | reporter.nih.gov |
| Role of Bacteria in Colitis-Associated Colon Cancer | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2023 | $858,754 | April 1, 2007 | April 30, 2025 | JOBIN, CHRISTIAN | reporter.nih.gov |
| Phase 1 Study of DNX-2440 for Resectable Colorectal Liver Metastasis - IND 018569 | NIH | National Cancer Institute | 2022 | $852,568 | September 1, 2022 | August 31, 2024 | ROBBINS, JOAN MARIE | reporter.nih.gov |
| 2/2 VSU-MCC Partnership for Cancer Disparities Research and Training program (SUCCEED) | NIH | National Cancer Institute | 2021 to 2024 | $843,034 | September 20, 2021 | August 31, 2025 | FAISON, MILTON O | reporter.nih.gov |
| Physical Signaling Mechanisms That Regulate Intestinal Architecture | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $836,190 | May 19, 2020 | April 30, 2024 | PACK, MICHAEL A | reporter.nih.gov |
| Activating p53 for colorectal cancer prevention | NIH | National Cancer Institute | 2021 to 2023 | $833,467 | June 12, 2018 | May 31, 2024 | WU, XIANGWEI | reporter.nih.gov |
| The regulation of mutant p53 protein accumulation in cancer: molecular basis and therapeutic potential | NIH | National Cancer Institute | 2021 to 2022 | $823,103 | July 1, 2021 | June 30, 2023 | FENG, ZHAOHUI | reporter.nih.gov |
| High Mobility Group A1 Chromatin Regulators in Colon Carcinogenesis | NIH | National Cancer Institute | 2021 to 2022 | $820,336 | July 24, 2018 | June 30, 2025 | RESAR, LINDA M S | reporter.nih.gov |
| Methods for Analyzing Cancer Somatic Mutation Data | NIH | National Cancer Institute | 2021 to 2022 | $805,199 | September 20, 2018 | August 31, 2025 | HE, QIANCHUAN | reporter.nih.gov |
| Understanding NLRP6 function in intestinal homeostasis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $800,348 | July 1, 2019 | April 30, 2023 | CHEN, GRACE Y. | reporter.nih.gov |
| Sex specific epigenetic regulation of colon cancer metastasis | NIH | National Cancer Institute | 2022 to 2023 | $799,225 | September 6, 2022 | August 31, 2028 | WANG, Y. ALAN | reporter.nih.gov |
| BET degraders for improving colorectal cancer therapy | NIH | National Cancer Institute | 2021 to 2022 | $797,550 | April 1, 2021 | March 31, 2026 | ZHANG, LIN | reporter.nih.gov |
| Understanding the full spectrum of epigenetic vulnerability in cancer through the delineation of DNA methylation function in gene 3' end | NIH | National Cancer Institute | 2021 to 2022 | $790,332 | February 1, 2019 | December 30, 2022 | TING, ANGELA H | reporter.nih.gov |
| Resistance Training to Reduce Chemotoxicity in Colon Cancer | NIH | National Cancer Institute | 2021 | $788,917 | June 15, 2017 | May 31, 2024 | CAAN, BETTE J | reporter.nih.gov |
| Colorectal Cancer Molecular Subtype Assay Development and Validation | NIH | National Cancer Institute | 2021 to 2023 | $787,854 | September 21, 2018 | August 31, 2025 | MARU, DIPEN M. | reporter.nih.gov |
| Enterotoxigenic B. fragilis Acquisition in Disease Susceptibility | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $787,500 | September 13, 2018 | August 31, 2024 | BUBECK WARDENBURG, JULIANE | reporter.nih.gov |
| Cell-specific nanocarrier with endocytic and endosomolytic activities for therapeutic genome editing | NIH | National Center for Advancing Translational Sciences | 2021 | $784,845 | August 22, 2019 | November 30, 2022 | LAM, KIT S | reporter.nih.gov |
| Progression, response, and resistance of RSPO fusion colorectal cancer | NIH | National Cancer Institute | 2021 to 2022 | $760,809 | August 1, 2018 | July 31, 2023 | DOW, LUKAS EDWARD | reporter.nih.gov |
| Extreme High Throughput Screening Via Massively Parallel Droplet Dispenser Arrays | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $754,805 | September 23, 2019 | August 31, 2024 | HUI, ELLIOT E | reporter.nih.gov |
| Scalable Clinical Decision Support for Individualized Cancer Risk Management | NIH | National Cancer Institute | 2021 | $749,164 | August 1, 2017 | December 31, 2022 | DEL FIOL, GUILHERME | reporter.nih.gov |
| Targeting Cancer through Suppressing Stress Induction of GRP78/BiP | NIH | National Cancer Institute | 2021 to 2022 | $747,327 | December 1, 2019 | November 30, 2023 | LEE, AMY S | reporter.nih.gov |
| Malignant Cell Engagement in Immune Circuits of Human Microsatellite-stable and Microsatellite-instable Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2023 | $747,000 | April 8, 2021 | August 31, 2024 | PELKA, KARIN | reporter.nih.gov |
| Genetics and Biology of Metastatic Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2022 | $746,515 | September 1, 2018 | August 31, 2023 | DEPINHO, RONALD ANTHONY | reporter.nih.gov |
| Microbial Metabolite Mimics, PXR and Colitis-Induced Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2022 | $746,393 | August 14, 2018 | July 31, 2024 | MANI, SRIDHAR | reporter.nih.gov |
| Coordinating Center for Population-based Research to Optimize Cancer Screening (PROSPR) (U24) | NIH | National Cancer Institute | 2021 | $743,093 | April 15, 2018 | March 31, 2022 | LI, CHRISTOPHER I | reporter.nih.gov |
| (PQ4) - Tools for simultaneous disruption of multiple epigenetically silenced genes for studying their roles in tumorigenesis using ex vivo human and mouse colon organoid and in vivo mouse models | NIH | National Cancer Institute | 2021 to 2022 | $741,665 | September 1, 2018 | August 31, 2024 | EASWARAN, HARIHARAN | reporter.nih.gov |
| Colonic responses to vitamin D and aspirin in African- and European-Americans | NIH | National Cancer Institute | 2021 to 2022 | $734,655 | July 3, 2018 | June 30, 2024 | KUPFER, SONIA | reporter.nih.gov |
| Effectiveness and Implementation of mPATH-CRC: a Mobile Health System for Colorectal Cancer Screening | NIH | National Cancer Institute | 2021 to 2022 | $734,252 | April 1, 2018 | March 31, 2024 | MILLER, DAVID P | reporter.nih.gov |
| Targeted Nanomedicines with Synergistic Chemotherapeutics to Enhance Immunotherapy of Metastatic Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2022 | $732,118 | July 1, 2018 | June 30, 2023 | LIN, WENBIN | reporter.nih.gov |
| Immunologic aspects of targeted therapy of erbB tumors | NIH | National Cancer Institute | 2021 to 2022 | $729,210 | April 1, 2018 | January 31, 2025 | GREENE, MARK I | reporter.nih.gov |
| Dietary Carcinogens for Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2022 | $724,680 | October 16, 2019 | May 31, 2023 | LI, YONG | reporter.nih.gov |
| The role of gene enhancer elements in colon cancer | NIH | National Cancer Institute | 2021 to 2023 | $724,672 | April 1, 2012 | December 31, 2023 | TESAR, PAUL JOSEPH | reporter.nih.gov |
| Mechanisms of lincDUSP Oncogenic Effects in Colon Cancer | NIH | National Cancer Institute | 2022 to 2023 | $721,844 | September 1, 2018 | August 31, 2025 | LAFRAMBOISE, THOMAS LOUIS | reporter.nih.gov |
| Improving Colorectal Cancer Screening and Risk Assessment through Deep Learning on Medical Images and Records | NIH | National Library of Medicine | 2021 to 2022 | $713,400 | February 12, 2019 | January 31, 2024 | HASSANPOUR, SAEED | reporter.nih.gov |
| Exosomes and platinum-induced peripheral neuropathy | NIH | National Cancer Institute | 2021 to 2022 | $709,918 | July 1, 2018 | June 30, 2024 | ZHANG, ZHENG GANG | reporter.nih.gov |
| The Functional Role of GRM3 in Colon Cancer | NIH | National Cancer Institute | 2021 to 2022 | $706,563 | March 14, 2017 | January 31, 2024 | WANG, JING | reporter.nih.gov |
| The Functional Role of LGR5 in Colon Cancer | NIH | National Cancer Institute | 2021 to 2022 | $706,563 | April 1, 2017 | January 31, 2024 | WANG, JING | reporter.nih.gov |
| Impact of germline variants on racial and ethnic differences in somatic mutation frequency | NIH | National Cancer Institute | 2021 to 2022 | $706,563 | March 1, 2018 | February 29, 2024 | TOLAND, AMANDA EWART | reporter.nih.gov |
| Mechanisms and therapeutic targeting of colon cancer stem cell plasticity | NIH | National Cancer Institute | 2021 to 2022 | $704,550 | April 1, 2018 | March 31, 2025 | CARMON, KENDRA S. | reporter.nih.gov |
| Oxalobacter formigenes-derived Factors Impact Hyperoxalemia, Hyperoxaluria, and Related Kidney Stones | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2023 | $699,600 | January 1, 2022 | December 31, 2025 | HASSAN, HATIM A | reporter.nih.gov |
| Molecular targeting the translational control axis in Wnt/beta-catenin signaling pathway | NIH | National Cancer Institute | 2021 to 2022 | $696,807 | August 1, 2017 | July 31, 2024 | ZHANG, JIAN-TING | reporter.nih.gov |
| Inactivation of MSH3 in Colorectal Cancer and Race | NIH | National Cancer Institute | 2021 to 2022 | $696,131 | August 1, 2021 | January 15, 2023 | CARETHERS, JOHN M | reporter.nih.gov |
| Role of Sulfiredoxin in Colorectal Cancer Development | NIH | National Cancer Institute | 2021 to 2022 | $692,826 | January 1, 2018 | December 31, 2023 | WEI, QIOU | reporter.nih.gov |
| Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy | NIH | National Cancer Institute | 2021 | $679,295 | April 5, 2017 | March 31, 2022 | LAUFFENBURGER, DOUGLAS A | reporter.nih.gov |
| Tumor-Associated Antigen Delivery using Protein Nanoparticles for Combined Immunotherapy | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2022 | $667,636 | April 1, 2019 | December 31, 2024 | WANG, SZU-WEN | reporter.nih.gov |
| Aggressive colorectal cancer subtypes and social disadvantage in a racially diverse cohort | NIH | National Cancer Institute | 2021 to 2022 | $655,223 | June 1, 2021 | July 31, 2022 | ROZEK, LAURA | reporter.nih.gov |
| Longitudinal Adherence to Colorectal Cancer Screening in the VA | NIH | National Cancer Institute | 2021 to 2023 | $653,681 | April 1, 2019 | March 31, 2025 | LIANG, PETER SHUANG | reporter.nih.gov |
| PCPT and SELECT Cohorts: Core Infrastructure Support for Cancer Research | NIH | National Cancer Institute | 2021 | $653,163 | September 20, 2013 | March 31, 2022 | TANGEN, CATHERINE M. | reporter.nih.gov |
| Development of novel metastatic mouse models that recapitulate the major immune contexts of human colon cancer | NIH | National Cancer Institute | 2021 to 2022 | $650,862 | December 1, 2019 | November 30, 2022 | JACKS, TYLER E. | reporter.nih.gov |
| Targeted Hyperpolarized Molecular Beacons for Colorectal Cancer Detection | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2023 | $648,000 | September 30, 2021 | July 31, 2025 | BHATTACHARYA, PRATIP K. | reporter.nih.gov |
| Systems Modeling of Tumor Heterogeneity and Therapy Response in Colorectal Cancer | NIH | National Cancer Institute | 2021 | $645,756 | June 1, 2017 | May 31, 2023 | GINTY, FIONA | reporter.nih.gov |
| A patient-centered intervention using virtual technology to reduce colorectal cancer disparities in primary care | NIH | National Cancer Institute | 2021 | $639,261 | February 1, 2017 | January 31, 2024 | LOK, BENJAMIN | reporter.nih.gov |
| Uncovering Roles of Metabolites in Colorectal Cancer Etiology | NIH | National Cancer Institute | 2021 to 2022 | $639,201 | August 1, 2020 | June 30, 2024 | SHU, XIANG | reporter.nih.gov |
| Implementing Universal Lynch Syndrome Screening across Multiple Healthcare Systems: Identifying Strategies to Facilitate and Maintain Programs in Different Organizational Contexts | NIH | National Cancer Institute | 2021 | $637,674 | August 1, 2017 | July 31, 2023 | RAHM, ALANNA K | reporter.nih.gov |
| Great Lakes New England Clinical Validation Center | NIH | National Cancer Institute | 2021 | $627,186 | May 15, 2000 | August 31, 2022 | BRENNER, DEAN E. | reporter.nih.gov |
| Comparative Effectiveness of Fecal Immunochemical Tests with Optical Colonoscopy | NIH | National Cancer Institute | 2021 | $623,145 | August 1, 2017 | June 30, 2023 | LEVY, BARCEY THURSTON | reporter.nih.gov |
| Precision therapeutics of inflammatory bowel disease guided by Boolean logic | NIH | National Center for Advancing Translational Sciences | 2021 to 2022 | $621,778 | August 28, 2020 | July 31, 2023 | SAHOO, DEBASHIS | reporter.nih.gov |
| Novel Strategies for Intervention of Inflammatory Diseases and Cancer | NIH | National Cancer Institute | 2021 to 2022 | $620,730 | July 1, 2004 | May 31, 2025 | WANG, RONGFU | reporter.nih.gov |
| CLINCIAL VALIDATION OF APC AND TP53 AS BIOMARKERS FOR CETUXIMAB RESPONSE | NIH | National Cancer Institute | 2021 to 2022 | $607,571 | July 3, 2019 | March 31, 2023 | YEATMAN, TIMOTHY J | reporter.nih.gov |
| Safer Approaches to CRC Chemoprevention | NIH | National Cancer Institute | 2021 | $607,251 | December 15, 2016 | November 30, 2023 | RAO, CHINTHALAPALLY V. | reporter.nih.gov |
| Global Measurements of Protein Folding Stability for Characterization of Aging and Disease | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $605,750 | September 23, 2019 | August 31, 2023 | FITZGERALD, MICHAEL C | reporter.nih.gov |
| Novel Path to Chronic Sensorimotor Dysfunction and Treatment for Chemotherapy | NIH | National Cancer Institute | 2021 to 2022 | $604,292 | September 13, 2018 | July 31, 2024 | COPE, TIMOTHY C | reporter.nih.gov |
| Development of 5hmC and 5mC biomarkers in cell-free circulating DNA for sensitive colon cancer detection and prognosis | NIH | National Cancer Institute | 2021 | $599,788 | August 1, 2017 | July 31, 2023 | BISSONNETTE, BRUCE MARC | reporter.nih.gov |
| Advanced Point-scanning Confocal Microscope for a Microscopy Core Facility | NIH | Office of the Director, National Institutes of Health | 2023 | $599,488 | September 15, 2023 | September 14, 2024 | AGUIRRE-GHISO, JULIO A. | reporter.nih.gov |
| Randomized Controlled Trial of Resistant Starch to Reduce Colon Cancer Risk in Alaska Native People | NIH | National Cancer Institute | 2021 | $596,049 | January 10, 2017 | December 31, 2022 | O'KEEFE, STEPHEN J.D. | reporter.nih.gov |
| Targeting Wnt-dependent colorectal cancer | NIH | National Cancer Institute | 2021 to 2022 | $594,046 | August 12, 2021 | February 29, 2024 | ROBBINS, DAVID J | reporter.nih.gov |
| A Major Nutritional Effect on Intestinal Stem Cells and Tumors | NIH | National Cancer Institute | 2021 to 2022 | $582,164 | July 17, 2018 | May 31, 2024 | AUGENLICHT, LEONARD H | reporter.nih.gov |
| Targeting VISTA eradicates large, established PD-1/CTLA-4 resistant tumors | NIH | National Cancer Institute | 2021 | $570,047 | May 1, 2017 | April 30, 2023 | NOELLE, RANDOLPH J. | reporter.nih.gov |
| Paid Sick Leave Mandates and Cancer Prevention | NIH | National Cancer Institute | 2021 to 2022 | $560,463 | August 5, 2019 | July 31, 2024 | CALLISON, KEVIN | reporter.nih.gov |
| Health care system-led familial risk notification: design and ethical assessment | NIH | National Human Genome Research Institute | 2021 to 2023 | $559,616 | September 20, 2018 | June 30, 2024 | BLASI, PAULA RAE | reporter.nih.gov |
| Task Order: Colorectal Cancer Prevention by a Novel EPA Analogue TP-252 and Naproxen in FAP and lynch syndrome models | NIH | National Cancer Institute | 2021 | $554,176 | September 15, 2019 | February 14, 2022 | KENNEDY, GREGORY | reporter.nih.gov |
| Sulindac sensitizes colorectal cancer to anti-PD-L1 therapy | NIH | National Cancer Institute | 2022 | $553,817 | August 15, 2022 | July 31, 2023 | XI, YAGUANG | reporter.nih.gov |
| STING-Activating Polymeric Nanovaccines for T Cell Therapy of Melanoma | NIH | National Cancer Institute | 2021 | $535,530 | September 30, 2017 | August 31, 2022 | GAO, JINMING | reporter.nih.gov |
| Developing an intervention to improve follow-up of abnormal fecal immunochemical test results in a safety-net population using a mixed methods approach | NIH | National Cancer Institute | 2021 to 2023 | $534,394 | September 1, 2019 | March 31, 2025 | ISSAKA, RACHEL B. | reporter.nih.gov |
| Functional Consequences of Racially Associated Ephrin Alterations on the Prostate Tumor Microenvironment | NIH | National Cancer Institute | 2021 to 2022 | $530,308 | July 3, 2019 | October 31, 2022 | FRANCO CORONEL, OMAR | reporter.nih.gov |
| An organotypic model recapitulating colon cancer microenvironment and metastasis | NIH | National Cancer Institute | 2021 | $521,870 | September 25, 2017 | August 30, 2024 | HUANG, EMINA HUI-NA | reporter.nih.gov |
| Harnessing the CRL4 ubiquitin ligase for antagonizing colorectal carcinogenesis | NIH | National Cancer Institute | 2021 | $517,885 | January 17, 2017 | December 31, 2023 | ZHOU, PENGBO | reporter.nih.gov |
| Novel Mcl-1 inhibitors for overcoming therapeutic resistance in colorectal cancer | NIH | National Cancer Institute | 2021 | $516,652 | June 5, 2017 | May 31, 2023 | NIKOLOVSKA-COLESKA, ZANETA | reporter.nih.gov |
| Investigating L1CAM-dependent stem cell regeneration in metastasis | NIH | National Cancer Institute | 2021 to 2022 | $513,638 | August 13, 2018 | July 31, 2023 | GANESH, KARUNA | reporter.nih.gov |
| Validation of blood-based predictive biomarkers of therapeutic response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer | NIH | National Cancer Institute | 2022 to 2023 | $511,837 | May 1, 2022 | April 30, 2024 | ARORA, SANJEEVANI | reporter.nih.gov |
| Behavioral Economics and Population-based Colorectal Cancer Screening | NIH | National Cancer Institute | 2021 to 2022 | $506,972 | September 15, 2018 | August 31, 2023 | MEHTA, SHIVAN JATIN | reporter.nih.gov |
| Improved Treatment of Colorectal Cancer with CF10 Diversity Supplement | NIH | National Cancer Institute | 2021 to 2022 | $500,917 | February 1, 2022 | July 31, 2022 | GMEINER, WILLIAM H. | reporter.nih.gov |
| How beta-catenin expands Foxp3+RORgammat+ Pro-inflammatory T-regulatory cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $498,990 | April 20, 2015 | June 30, 2022 | GOUNARI, FOTINI | reporter.nih.gov |
| Characterization of microbial and host requirements for colonic biofilm assembly and biofilm-mediated colon tumorigenesis | NIH | National Cancer Institute | 2021 to 2022 | $497,999 | September 1, 2020 | August 30, 2024 | DREWES, JULIA L | reporter.nih.gov |
| Mechanisms of gut epithelial DUOX-mediated intestinal homeostasis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $497,721 | April 1, 2018 | January 31, 2023 | KAO, JOHN Y | reporter.nih.gov |
| (PQ6) Radiogenomics of colorectal polyps to assess benign proliferative vs. premalignant states. | NIH | National Cancer Institute | 2021 | $491,493 | September 21, 2017 | March 31, 2022 | GRADY, WILLIAM MALLORY | reporter.nih.gov |
| Effectiveness of screening for colorectal cancer in average risk adults: Colonoscopy vs FIT | NIH | National Cancer Institute | 2021 | $490,729 | April 10, 2017 | June 30, 2022 | DOUBENI, CHYKE ABADAMA | reporter.nih.gov |
| Multidisciplinary Study of Folate Intake and Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2022 | $481,357 | August 10, 2021 | February 29, 2024 | ZHANG, XUEHONG | reporter.nih.gov |
| The role of PGC1beta and ERRalpha as novel targets for therapy in colorectal cancer | NIH | National Cancer Institute | 2021 to 2022 | $475,164 | July 2, 2018 | June 30, 2023 | FISHER, KURT | reporter.nih.gov |
| Development of nanoparticulate solution for cancer treatment by breakup of tumor extracellular hydroxyapatite: a new paradigm | NIH | National Cancer Institute | 2021 | $472,960 | May 1, 2021 | April 30, 2024 | TANTAWY, MOHAMMED NOOR | reporter.nih.gov |
| Role of necroptosis in colorectal cancer therapy | NIH | National Cancer Institute | 2023 | $461,812 | June 1, 2023 | May 31, 2025 | ZHANG, LIN | reporter.nih.gov |
| Ultra-bright fluorescent nanoparticles for colorectal adenoma detection | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $461,090 | July 27, 2021 | May 31, 2024 | ROPER, JATIN | reporter.nih.gov |
| Targeting DNA Mismatches for Auger Electron Radiotherapy | NIH | National Cancer Institute | 2023 | $457,607 | September 8, 2023 | August 31, 2025 | ZEGLIS, BRIAN MATTHEW | reporter.nih.gov |
| Development of Drug Detoxifying Bacteria for Chemotherapy Induced Gut Injury | NIH | National Cancer Institute | 2021 to 2022 | $454,955 | September 23, 2021 | August 31, 2022 | SINGH, RASHIM | reporter.nih.gov |
| A Pilot Study to Evaluate the Benefits of Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy | NIH | National Cancer Institute | 2022 | $452,540 | September 23, 2022 | August 31, 2025 | LEE, RICHARD T | reporter.nih.gov |
| The role of the senescent microenvironment on cancer initiating cells in the colon. | NIH | National Institute on Aging | 2021 | $451,960 | September 30, 2021 | March 31, 2022 | GRADY, WILLIAM MALLORY | reporter.nih.gov |
| Neoadjuvant PD-1 blockade in mismatch repair deficient rectal cancer | NIH | National Cancer Institute | 2021 to 2022 | $450,975 | February 1, 2021 | January 31, 2024 | CERCEK, ANDREA | reporter.nih.gov |
| Patient-derived organoids reveal rectal cancers develop radiosensitivity | NIH | National Cancer Institute | 2021 to 2022 | $450,147 | February 5, 2021 | January 31, 2024 | KOLESNICK, RICHARD N | reporter.nih.gov |
| CDHR5 tumor suppressor function in the intestine | NIH | National Cancer Institute | 2021 | $449,218 | September 1, 2021 | August 31, 2025 | CRAWLEY, WILLIAM SCOTT | reporter.nih.gov |
| Gut Microbiome, Antibiotic Use & Colon Cancer Recurrence | NIH | National Cancer Institute | 2021 | $446,142 | September 25, 2017 | August 31, 2025 | FEDIRKO, VERONIKA | reporter.nih.gov |
| Virulence determinants of Fusobacterium nucleatum | NIH | National Institute of Dental & Craniofacial Research | 2021 | $443,892 | September 1, 2018 | August 31, 2023 | TON-THAT, HUNG | reporter.nih.gov |
| Strategy for Safe Colon-targeted Local Therapy of Inflammatory Bowel Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $441,111 | September 22, 2021 | June 30, 2025 | TUMMALA, HEMACHAND | reporter.nih.gov |
| Gut microbiota-derived signaling in liver carcinogenesis and cancer treatment | NIH | National Cancer Institute | 2021 to 2023 | $440,819 | September 19, 2019 | August 31, 2024 | HU, YING | reporter.nih.gov |
| Designer EcN for treatment of solid tumors | NIH | National Cancer Institute | 2022 to 2023 | $440,436 | March 1, 2022 | February 28, 2025 | LESSER, CAMMIE | reporter.nih.gov |
| Development of PDE5 Inhibitors for Localized Delivery to Prevent Colorectal Cancer | NIH | National Cancer Institute | 2021 | $439,332 | August 1, 2021 | January 31, 2025 | MIAO, SHAOBIN | reporter.nih.gov |
| Visualization and Epigenomic Characterization of Early Intestinal Tumorigenesis in Mice | NIH | National Cancer Institute | 2021 | $434,625 | January 5, 2017 | December 31, 2021 | LAIRD, PETER W | reporter.nih.gov |
| Estrogenic protection against colorectal cancer development in obesity | NIH | National Cancer Institute | 2023 | $433,500 | July 19, 2023 | June 30, 2026 | SHI, HAIFEI | reporter.nih.gov |
| (PQ1) Mechanisms for Early Onset Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2022 | $430,036 | August 1, 2021 | July 31, 2024 | ROSENBERG, DANIEL WILLIAM | reporter.nih.gov |
| Defining the role of S1p and myeloid cells during enterotoxigenic B. fragilis infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $429,750 | September 22, 2021 | August 31, 2024 | DENG, ZHONG-BIN | reporter.nih.gov |
| Targeting the kinome in K-ras driven colorectal cancers | NIH | National Cancer Institute | 2021 | $427,763 | December 8, 2016 | November 30, 2022 | DUNCAN, JAMES STUART | reporter.nih.gov |
| In vivo CRISPR-screening of novel cancer cell-intrinsic targets that sensitize to local ionizing radiation, and possible combination with systemic checkpoint blockade. | NIH | National Cancer Institute | 2022 to 2023 | $425,653 | August 16, 2022 | July 31, 2025 | WEICHSELBAUM, RALPH R | reporter.nih.gov |
| Altered Lipid Metabolism as a Novel Target for Colon Cancer Treatment | NIH | National Cancer Institute | 2021 | $425,312 | August 1, 2017 | July 31, 2023 | EVERS, BERNARD MARK | reporter.nih.gov |
| A novel Drosophila platform for sequential genetic manipulations in vivo | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $423,500 | July 1, 2021 | June 30, 2024 | BASS, HENRY W | reporter.nih.gov |
| Paracrine Role of Endothelial Cells in HER3-Mediated Colon Cancer Cell Survival | NIH | National Cancer Institute | 2021 to 2022 | $420,869 | May 1, 2020 | April 30, 2024 | WANG, RUI | reporter.nih.gov |
| Implementing and Evaluating Genetic Screening in Healthy Adults for Precision Public Health | NIH | National Human Genome Research Institute | 2022 | $420,769 | September 1, 2022 | August 31, 2024 | ROBERTS, MEGAN C. | reporter.nih.gov |
| Breast, Colorectal, and Ovary Cancer Clinical Validation Center | NIH | National Cancer Institute | 2021 | $418,953 | August 16, 2010 | March 31, 2022 | LI, CHRISTOPHER I | reporter.nih.gov |
| Interrupting tumor progression by restoration of VDR expression | NIH | National Cancer Institute | 2022 to 2023 | $417,085 | April 1, 2022 | March 31, 2025 | NAKANISHI, MASAKO | reporter.nih.gov |
| Biomarkers for Early Detection of Colorectal Cancer in Ulcerative Colitis | NIH | National Cancer Institute | 2021 to 2022 | $415,805 | June 19, 2017 | May 31, 2024 | CHEN, RU | reporter.nih.gov |
| Racial Disparities and Colorectal DNA Methylation- Driven Gene Expression | NIH | National Cancer Institute | 2023 | $415,257 | September 15, 2023 | August 31, 2025 | LI, LI | reporter.nih.gov |
| Hes1-loss promotes dysregulation of epithelial homeostasis and inflammation in a serrated adenocarcinoma model | NIH | National Cancer Institute | 2021 to 2022 | $415,164 | July 1, 2018 | March 31, 2023 | ZHOU, LAN | reporter.nih.gov |
| Modulation of microbiome function by host-derived noncoding small RNA | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $414,965 | June 1, 2021 | November 30, 2023 | JOBIN, CHRISTIAN | reporter.nih.gov |
| Development of a novel imaging modality for adoptive cell therapy | NIH | National Cancer Institute | 2021 | $413,974 | September 17, 2021 | August 31, 2023 | WALD, DAVID | reporter.nih.gov |
| Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study | NIH | National Cancer Institute | 2021 to 2022 | $412,901 | September 1, 2018 | July 15, 2023 | WILLIAMS, GRANT R | reporter.nih.gov |
| Engaging diverse colorectal cancer survivors in the design of an adaptive text message-based intervention to improve diet quality | NIH | National Cancer Institute | 2022 to 2023 | $410,906 | August 1, 2022 | June 30, 2024 | VAN BLARIGAN, ERIN LYNN | reporter.nih.gov |
| Understanding and Targeting Tiam1 in Cancer | NIH | National Cancer Institute | 2021 to 2022 | $410,209 | January 1, 2021 | December 31, 2023 | MANOR, DANNY | reporter.nih.gov |
| Super Natural Killer Cells That Target Metastases in the Tumor-Draining Lymph Nodes | NIH | National Cancer Institute | 2021 | $409,817 | December 23, 2016 | November 30, 2022 | KING, MICHAEL R. | reporter.nih.gov |
| Inhibition of CaMKK2 sensitizes rectal cancers to radiation therapy | NIH | National Cancer Institute | 2021 to 2022 | $409,455 | January 1, 2021 | December 31, 2022 | ROPER, JATIN | reporter.nih.gov |
| Microfluidic Droplet Organoids to Decipher the Tumor Heterogeneity in CRC of African Ancestry | NIH | National Cancer Institute | 2022 to 2023 | $409,455 | March 1, 2022 | February 28, 2025 | HSU, SHIAOWEN DAVID | reporter.nih.gov |
| Cancer-specific metabolites as cues to engineer and target anti-tumor therapeutic bacteria | NIH | National Cancer Institute | 2022 to 2023 | $409,455 | August 1, 2022 | July 31, 2025 | DWIDAR, MOHAMMED | reporter.nih.gov |
| Integration of Genomic and Clinical Data to Enhance Subtyping of Colon Cancer | NIH | National Cancer Institute | 2021 | $407,754 | January 18, 2017 | June 30, 2022 | SINICROPE, FRANK A. | reporter.nih.gov |
| Biomarkers for Reducing Mortality of Cancers of the Colon and Esophagus | NIH | National Cancer Institute | 2021 | $407,598 | August 25, 2010 | September 30, 2022 | MARKOWITZ, SANFORD D. | reporter.nih.gov |
| Epigenomic analysis of cell-free nucleosomes for cancer research | NIH | National Cancer Institute | 2023 | $406,374 | July 1, 2023 | June 30, 2024 | VENTERS, BRYAN J | reporter.nih.gov |
| Role of genetic and epigenetic alterations in CFTR in colorectal cancer | NIH | National Cancer Institute | 2021 to 2022 | $405,711 | July 26, 2021 | June 30, 2024 | PRIZMENT, ANNA | reporter.nih.gov |
| PG545 synergizes with PARP inhibitors in ovarian cancer to disrupt DNA repair through modulation of DEK-RAD51 axis | NIH | National Cancer Institute | 2022 to 2023 | $404,369 | February 1, 2022 | January 31, 2025 | SHRIDHAR, VIJI | reporter.nih.gov |
| Application of mucus modulating multipurpose trypsin nanoparticles to overcome the mucus barrier and deliver mitochondria-targeted anticancer drugs in mucinous carcinoma peritonei | NIH | National Cancer Institute | 2022 to 2023 | $404,369 | September 1, 2022 | August 31, 2025 | CHOUDRY, MOHAMMAD HAROON ASIF | reporter.nih.gov |
| Are racial disparities in colon cancer due to epigenetic outliers. | NIH | National Cancer Institute | 2021 to 2022 | $403,839 | July 16, 2021 | June 30, 2024 | SAPIENZA, CARMEN | reporter.nih.gov |
| Clinical biomarker for early prediction of chemotherapy-induced peripheral neuropathy | NIH | National Cancer Institute | 2023 | $403,240 | September 19, 2023 | August 31, 2025 | HAROUTOUNIAN, SIMON | reporter.nih.gov |
| CDK4/6 inhibition: a novel therapeutic strategy for GNAS-mutant gastrointestinal malignancies | NIH | National Cancer Institute | 2022 to 2023 | $401,826 | August 2, 2022 | June 30, 2025 | LOWY, ANDREW M | reporter.nih.gov |
| Cancer therapy with a combination of oncolytic bacteria and virus to enhance targeted cell killing and anti-tumor immune responses | NIH | National Cancer Institute | 2021 to 2022 | $400,018 | December 15, 2020 | November 30, 2023 | KONG, WEI | reporter.nih.gov |
| Efficacy of an Electrophile Scavenger in the Prevention of Gastrointestinal Inflammatory Carcinogenesis | NIH | National Cancer Institute | 2021 | $400,000 | April 9, 2021 | September 30, 2023 | RATHMACHER, JOHN A | reporter.nih.gov |
| TOPIC 418 "HIGH THROUGHPUT SPATIALOMICS PROFILING FOR THICK TUMORTISSUES" | NIH | National Cancer Institute | 2021 | $400,000 | September 16, 2021 | June 15, 2022 | HAUSER, ALAN | reporter.nih.gov |
| Exonuclease Based Microsatellite Sequencing | NIH | National Cancer Institute | 2022 | $400,000 | April 12, 2022 | March 31, 2024 | ERVIN, ERIC | reporter.nih.gov |
| Development of drug conjugates of R-spondin peptibodies for the treatment of colorectal cancer | NIH | National Cancer Institute | 2023 | $400,000 | May 1, 2023 | April 30, 2025 | CUI, JIE | reporter.nih.gov |
| Microsatellite Instability Sequencing via Single-Molecule DNA Re-Reading | NIH | National Cancer Institute | 2023 | $400,000 | September 18, 2023 | March 31, 2025 | SCHIBEL, ANNA | reporter.nih.gov |
| SBIR Topic #446 Phase I -Development of Senotherapeutic Agents for Cancer Treatment | NIH | National Cancer Institute | 2023 | $400,000 | September 25, 2023 | September 24, 2024 | FROST, GRANT B | reporter.nih.gov |
| SBIR PHASE I TOPIC 431, INTEGRATED CELL CULTURE CHAMBER AND FLOW GUIDE FOR POC, WALK-AWAY OPERATION FOR AUTOLOGOUS T CELL MANUFACTURING | NIH | National Cancer Institute | 2022 | $398,625 | September 15, 2022 | September 14, 2023 | MONTY, NATHAN | reporter.nih.gov |
| Preclinical Evaluation of a Novel ADAM10 Modulator to Treat ColorectalCancer | NIH | National Cancer Institute | 2023 | $397,916 | May 10, 2023 | April 30, 2024 | PREMSRIRUT, PREM KHOVABUTR | reporter.nih.gov |
| Development of Novel Combination Strategies to Overcome Resistance to KRASG12C Inhibition in Colorectal Cancers | NIH | National Cancer Institute | 2022 to 2023 | $397,469 | August 1, 2022 | July 31, 2025 | LEOPOLD, JUDITH S | reporter.nih.gov |
| Microbiome-derived regulators of therapy-resistant colorectal tumors | NIH | National Cancer Institute | 2022 to 2023 | $397,033 | August 9, 2022 | July 31, 2025 | GRIFFIN, TIMOTHY J. | reporter.nih.gov |
| Novel Antibody-Drug Conjugate Combination Therapy for Treating Colorectal Cancer | NIH | National Cancer Institute | 2022 to 2023 | $396,739 | February 1, 2022 | January 31, 2025 | CARMON, KENDRA S. | reporter.nih.gov |
| Organoid modeling of pre-metastatic niche formation in the liver by primary colorectal tumor secreted factors | NIH | National Cancer Institute | 2022 to 2023 | $395,529 | August 23, 2022 | January 31, 2025 | SKARDAL, ALEKSANDER | reporter.nih.gov |
| Cancer Hijacks Enzyme Substrate Mutations to Facilitate Tumorigenesis | NIH | National Cancer Institute | 2022 to 2023 | $395,468 | May 1, 2022 | April 30, 2025 | LIU, PENGDA | reporter.nih.gov |
| L1 element mutagenesis as a driver of epithelial cancers in African Americans | NIH | National Cancer Institute | 2022 to 2023 | $393,647 | January 1, 2022 | December 31, 2024 | DEVINE, SCOTT E | reporter.nih.gov |
| Biodegradable nanocarriers and antibodies as targeting delivery vehicles for cancer metallodrugs | NIH | National Institute of General Medical Sciences | 2021 | $392,500 | June 1, 2018 | July 31, 2023 | CONTEL, MARIA | reporter.nih.gov |
| Colorectal screening fear-reduction and racially-targeted norm messaging entreaties to increase colorectal cancer screening rates among African Americans | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2023 | $392,495 | September 25, 2021 | June 30, 2025 | MANNING, MARK A | reporter.nih.gov |
| Understanding the full spectrum of epigenetic vulnerability in cancer through the delineation of DNA methylation function in gene 3' end | NIH | National Cancer Institute | 2023 | $392,412 | January 19, 2023 | March 31, 2025 | TING, ANGELA H | reporter.nih.gov |
| Exploration of Novel Mutation Biomarkers to Repurpose EGFRi for Mutant KRAS Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2022 | $392,146 | July 15, 2021 | June 30, 2025 | FLOROU, VAIA | reporter.nih.gov |
| Optimizing the Population Representativeness of Older Adults in Cancer Trials | NIH | National Cancer Institute | 2021 | $392,116 | April 8, 2021 | March 31, 2024 | BIAN, JIANG | reporter.nih.gov |
| ctDNA for the Early Detection and Monitoring of Colorectal Cancer | NIH | National Cancer Institute | 2021 | $390,867 | September 7, 2010 | March 31, 2022 | SCHOEN, ROBERT E. | reporter.nih.gov |
| A HTS Approach to Discover Guanine Nucleotide-Competitive Inhibitors of Oncogenic KRAS | NIH | National Cancer Institute | 2021 | $389,545 | September 13, 2018 | August 31, 2023 | ROSSMAN, KENT | reporter.nih.gov |
| Chronic Kidney Disease Development in Cancer Treatment and Survival | NIH | National Cancer Institute | 2021 | $389,545 | September 16, 2021 | December 31, 2023 | HILL, DEIRDRE | reporter.nih.gov |
| Engineered Enteric Nervous System-Peri Neural Invasion platform to improve predictive preclinical screens in early-stage colorectal adenocarcinomas | NIH | National Cancer Institute | 2021 to 2022 | $388,972 | July 1, 2021 | June 30, 2024 | RAGHAVAN, SHREYA | reporter.nih.gov |
| Validating p53 Ser46 crotonylation as a potential target for possible anti-cancer therapy | NIH | National Cancer Institute | 2022 to 2023 | $387,941 | July 26, 2022 | June 30, 2025 | LU, HUA | reporter.nih.gov |
| Bacteriophage-mediated microbiota modification to prevent colorectal cancer development | NIH | National Cancer Institute | 2022 to 2023 | $387,838 | May 10, 2022 | February 28, 2025 | EL HADDAD, LYNN | reporter.nih.gov |
| Mechanisms of cell death and autophagy in intestinal epithelial cells in inflammation and cancer | NIH | National Cancer Institute | 2021 | $387,731 | March 21, 2017 | February 28, 2022 | MOSCAT, JORGE | reporter.nih.gov |
| A large animal model to elucidate the role of LGR5 stem cells in cancer | NIH | National Cancer Institute | 2021 to 2022 | $387,278 | February 1, 2021 | January 31, 2024 | PIEDRAHITA, JORGE A | reporter.nih.gov |
| Development of Superior Chelation Chemistry for 89Zr-ImmunoPET Imaging | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 | $386,534 | September 15, 2020 | July 31, 2022 | CHONG, HYUN-SOON | reporter.nih.gov |
| Pragmatic randomized trial of polygenic risk scoring for common diseases in primary care | NIH | National Human Genome Research Institute | 2021 | $386,100 | September 1, 2019 | June 30, 2022 | VASSY, JASON L | reporter.nih.gov |
| Suppression of Dominant-Negative Transcripts Escaping from Nonsense-Mediated mRNA Decay | NIH | National Institute of General Medical Sciences | 2022 to 2023 | $383,110 | September 20, 2022 | August 31, 2024 | KUROSAKI, TATSUAKI | reporter.nih.gov |
| Spatially Resolved Metagenomics to Explore Tumor-Microbiome Interactions in Human Colorectal Cancer | NIH | National Cancer Institute | 2021 | $383,077 | September 1, 2019 | August 31, 2023 | DE VLAMINCK, IWIJN | reporter.nih.gov |
| Cell type and molecular determinants of colorectal cancer initiation downstream of APC inactivation | NIH | National Cancer Institute | 2021 | $382,375 | June 1, 2017 | May 31, 2023 | LENGNER, CHRISTOPHER JOACHIM | reporter.nih.gov |
| MicroRNA regulation of endothelial DNA repair to enhance anti-tumor immunity | NIH | National Heart, Lung, and Blood Institute | 2021 | $382,183 | July 20, 2018 | April 30, 2023 | ANAND, SUDARSHAN | reporter.nih.gov |
| Anticancer Effects of a Repurposed Drug in Colon Cancer | NIH | National Cancer Institute | 2023 | $381,834 | September 1, 2023 | August 31, 2025 | DATTA, PRAN K | reporter.nih.gov |
| Development of a patient-derived organotypic spheroids (PDOTS) platform for prediction of clinical responses to immuno-oncology drugs | NIH | National Cancer Institute | 2021 | $381,800 | September 1, 2021 | August 31, 2022 | AREF, AMIR REZA | reporter.nih.gov |
| Spectral precision imaging for early diagnosis of colorectal lesions with CT colonography | NIH | National Cancer Institute | 2021 to 2022 | $380,147 | December 1, 2017 | November 30, 2024 | YOSHIDA, HIROYUKI | reporter.nih.gov |
| CRL3KEAP1 complex licenses genotoxic stress-induced tumor cell death | NIH | National Cancer Institute | 2021 to 2022 | $380,098 | April 1, 2021 | March 31, 2023 | GONG, YI-NAN | reporter.nih.gov |
| Understanding the regulatory role and therapeutic potential of long non-coding RNAs in metastatic colorectal cancer | NIH | National Cancer Institute | 2021 to 2022 | $378,924 | July 1, 2020 | June 30, 2024 | SILVA-FISHER, JESSICA | reporter.nih.gov |
| Ex Vivo Profiling of Immunotherapy Combinations Using Organotypic Tumor Spheroids | NIH | National Cancer Institute | 2021 to 2022 | $378,260 | August 16, 2018 | July 31, 2023 | JENKINS, RUSSELL WILLIAM | reporter.nih.gov |
| Abnormal Food Timing and Circadian Dyssynchrony in Alcohol Induced Colon Carcinogenesis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2022 | $378,000 | June 10, 2018 | May 31, 2023 | BISHEHSARI, FARAZ | reporter.nih.gov |
| Deciphering the Code for Senescence Escape During Cancer Progression in Humans | NIH | National Cancer Institute | 2021 | $376,527 | August 9, 2010 | January 31, 2024 | HERBIG, UTZ | reporter.nih.gov |
| Novel effects of xenoestrogens and gut microbiota derived estrogenic compounds in colonic inflammation | NIH | National Institute of Environmental Health Sciences | 2022 | $374,998 | September 6, 2022 | May 31, 2024 | JAYARAMAN, ARUL | reporter.nih.gov |
| The role of butyrate-producing bacteria in CIMP colorectal cancer tumorigenesis | NIH | National Cancer Institute | 2021 | $373,477 | March 15, 2017 | February 28, 2022 | WILLIAMS, BRENT LAMONT | reporter.nih.gov |
| Signature-guided therapy for mismatch repair defective cancers | NIH | National Cancer Institute | 2021 | $373,331 | August 1, 2017 | July 31, 2023 | LIN, SHIAW-YIH | reporter.nih.gov |
| The role of leukemia inhibitory factor in colorectal cancer | NIH | National Cancer Institute | 2022 | $372,497 | February 1, 2022 | January 31, 2023 | HU, WENWEI | reporter.nih.gov |
| The LIN28b-Let7-IMP1 axis in colonic epithelial biology | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $371,155 | March 1, 2000 | May 31, 2022 | RUSTGI, ANIL K | reporter.nih.gov |
| Stimulating Lymphocyte Activation Combined with Inhibition of Immunosuppressive Signals in Colon Cancer Metastases | NIH | National Cancer Institute | 2021 | $365,771 | January 22, 2020 | December 31, 2024 | MAKER, AJAY V. | reporter.nih.gov |
| Utility of Random Biopsies in Inflammatory Bowel Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 | $365,625 | September 21, 2022 | August 31, 2024 | LEWIS, JAMES D | reporter.nih.gov |
| Selenium Chemoprevention: Benefits and Harms | NIH | National Cancer Institute | 2021 | $364,547 | July 1, 2011 | May 31, 2022 | JACOBS, ELIZABETH T | reporter.nih.gov |
| SENP6, a novel p53 negative regulator, is an important new player in cancer | NIH | National Cancer Institute | 2021 | $363,713 | July 1, 2018 | June 30, 2022 | FENG, ZHAOHUI | reporter.nih.gov |
| Endogenous and Dietary Sphingolipids as Modulators in Inflammatory Bowel Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $363,375 | June 15, 2018 | May 31, 2023 | SABA, JULIE D | reporter.nih.gov |
| Beyond Body Mass Index: Bringing Body Composition into Oncology Practice | NIH | National Cancer Institute | 2021 to 2022 | $358,714 | April 1, 2018 | March 31, 2023 | FELICIANO, ELIZABETH MARJORIE CESPEDES | reporter.nih.gov |
| Guanylin GUCY2C axis in Colorectal Cancer Initiation | NIH | National Cancer Institute | 2021 | $357,970 | January 1, 2017 | December 31, 2022 | WALDMAN, SCOTT A | reporter.nih.gov |
| Targeting TGFbeta/PDK4 to Overcome Drug Resistance in Colorectal Cancer | NIH | National Cancer Institute | 2021 | $356,850 | August 16, 2018 | August 31, 2022 | WANG, JING | reporter.nih.gov |
| SENP6, a novel p53 negative regulator, is an important new player in cancer | NIH | National Cancer Institute | 2022 | $356,438 | July 1, 2018 | June 30, 2024 | FENG, ZHAOHUI | reporter.nih.gov |
| Network-Based Novel Therapeutics in Colorectal Cancers | NIH | National Center for Advancing Translational Sciences | 2022 | $355,500 | September 11, 2019 | July 31, 2023 | GHOSH, PRADIPTA | reporter.nih.gov |
| Precision therapeutics of inflammatory bowel disease guided by Boolean logic | NIH | National Center for Advancing Translational Sciences | 2023 | $355,500 | August 28, 2020 | July 31, 2024 | SAHOO, DEBASHIS | reporter.nih.gov |
| G-CSF inhibition as a colorectal cancer therapy | NIH | National Cancer Institute | 2021 | $355,323 | July 6, 2016 | June 30, 2023 | BESWICK, ELLEN J. | reporter.nih.gov |
| A Novel Device Alternative to Temporary Diverting Ostomies after Rectal Cancer Surgery | NIH | National Cancer Institute | 2021 to 2022 | $353,509 | June 22, 2022 | January 31, 2023 | FONG, KENTON DODYAN | reporter.nih.gov |
| Site-specific epigenetic activation of TP53 to improve cancer therapy | NIH | National Institute of General Medical Sciences | 2021 | $350,000 | September 16, 2021 | September 15, 2023 | HATHAWAY, NATHANIEL A. | reporter.nih.gov |
| Surgery triggered immune response and liver metastases | NIH | National Cancer Institute | 2021 to 2022 | $348,373 | January 1, 2018 | June 26, 2022 | TSUNG, ALLAN | reporter.nih.gov |
| DNA damage signaling to immune checkpoints | NIH | National Cancer Institute | 2021 | $347,953 | January 1, 2017 | December 31, 2022 | BAKKENIST, CHRISTOPHER J. | reporter.nih.gov |
| Role of HOS in Cell Transformation and Apoptosis | NIH | National Cancer Institute | 2021 | $344,138 | March 1, 2001 | November 30, 2021 | FUCHS, SERGE Y | reporter.nih.gov |
| Functional characterization of novel oncogenic loci driving progression and immune response in gastrointestinal cancer | NIH | National Cancer Institute | 2021 to 2022 | $343,440 | September 1, 2021 | February 28, 2023 | LO, YUAN-HUNG | reporter.nih.gov |
| The role of Dclk1 in the initiation of colorectal cancer | NIH | National Cancer Institute | 2021 | $338,550 | June 15, 2017 | May 31, 2023 | HOUCHEN, COURTNEY WAYNE | reporter.nih.gov |
| A phase-1 trial of intraperitoneal 5-fluorouracil and oxaliplatin in patients with colorectal cancer and unresectable peritoneal metastasis. | NIH | National Cancer Institute | 2023 | $336,425 | September 12, 2023 | August 31, 2025 | MITTRA, ARJUN | reporter.nih.gov |
| Mechanism of colon cancer metastasis: combined role of activin and TGF-beta signaling | NIH | National Cancer Institute | 2021 | $332,601 | September 27, 2010 | March 31, 2023 | JUNG, BARBARA H | reporter.nih.gov |
| Increasing Colorectal Cancer Screening in Alaska Native Men | NIH | National Institute of Nursing Research | 2021 to 2022 | $331,502 | June 18, 2021 | June 30, 2024 | MULLER, CLEMMA JACOBSEN | reporter.nih.gov |
| Implementation and Impact of Cancer Screening Navigation by Community Health Workers in Two National Screening Programs | NIH | National Cancer Institute | 2021 to 2022 | $329,385 | September 15, 2018 | August 31, 2024 | BARRINGTON, WENDY ELIZABETH | reporter.nih.gov |
| Uncovering the Role of Colorectal Stem Cells on Disease Penetrance in Lynch Syndrome | NIH | National Cancer Institute | 2021 | $320,000 | September 12, 2017 | August 31, 2023 | VILAR SANCHEZ, EDUARDO | reporter.nih.gov |
| Identification of Microbiome Based Markers to Improve Colorectal Cancer Detection | NIH | National Cancer Institute | 2021 | $319,318 | January 15, 2018 | December 31, 2021 | SCHLOSS, PATRICK DAVID | reporter.nih.gov |
| Diabetes, Medications and the Cost-Effectiveness of Screening for Colorectal Neoplasia | NIH | National Cancer Institute | 2021 to 2022 | $316,306 | September 1, 2018 | August 31, 2024 | HARDIKAR, SHEETAL | reporter.nih.gov |
| Network-Based Novel Therapeutics in Colorectal Cancers | NIH | National Center for Advancing Translational Sciences | 2021 | $316,000 | September 11, 2019 | July 31, 2022 | GHOSH, PRADIPTA | reporter.nih.gov |
| Detection of microsatellite instability biomarkers for therapeutic clinical trial eligibility | NIH | National Cancer Institute | 2021 | $314,062 | September 25, 2017 | March 31, 2022 | ROYCHOWDHURY, SAMEEK | reporter.nih.gov |
| Optimizing Colorectal Cancer Screening among Patients with Diabetes in Safety-Net Primary Care Settings: Targeting Implementation Approaches | NIH | National Cancer Institute | 2021 to 2022 | $313,199 | January 1, 2021 | May 31, 2022 | O'MALLEY, DENALEE M. | reporter.nih.gov |
| Coordinate roles of histone H3K27me3 and DNA methylation in intestinal homeostasis and tumorigenesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $310,608 | January 1, 2018 | November 30, 2022 | JADHAV, UNMESH | reporter.nih.gov |
| Novel Molecular Biomarkers and Therapeutics for Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2022 | $310,128 | September 18, 2018 | August 31, 2023 | FINK, STEPHEN PAUL | reporter.nih.gov |
| CLINCIAL VALIDATION OF APC AND TP53 AS BIOMARKERS FOR CETUXIMAB RESPONSE | NIH | National Cancer Institute | 2023 | $309,375 | April 1, 2023 | March 31, 2025 | YEATMAN, TIMOTHY J | reporter.nih.gov |
| Improving Routine Asymptomatic Cancer Screening among Federally Qualified Health Center Users in Florida: Application of a Health Literacy Framework | NIH | National Cancer Institute | 2021 to 2022 | $309,240 | April 1, 2018 | March 31, 2023 | BEST, ALICIA LYNETTE | reporter.nih.gov |
| NCI PATTERNS OF CARE STUDY - DIAGNOSIS YEAR 2020 BREAST CANCER AND COLORECTAL CANCER | NIH | National Cancer Institute | 2023 | $303,638 | December 23, 2022 | December 22, 2023 | SHRESTHA, ANSHU | reporter.nih.gov |
| Use of a Novel Toilet Seat to Passively Collect Digital Biomarkers in Assisted Living Settings | NIH | National Institute on Aging | 2021 | $299,676 | September 1, 2021 | August 31, 2024 | BAYAT SARMADI, PARMOON | reporter.nih.gov |
| A microscope for ultra-high multiplex spatial imaging of transcripts and proteins in tissues | NIH | Office of the Director, National Institutes of Health | 2023 | $299,500 | April 1, 2023 | March 31, 2024 | HACOHEN, NIR | reporter.nih.gov |
| A novel thermogel for topical treatment of ulcerative colitis with microbialmetabolite mimicry. | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 | $296,475 | June 1, 2023 | May 31, 2025 | LINHARDT, JEFFREY | reporter.nih.gov |
| Spatial Molecular Imager for Translational Research | NIH | Office of the Director, National Institutes of Health | 2023 | $295,000 | May 15, 2023 | May 14, 2024 | FRAIETTA, JOSEPH ANTHONY | reporter.nih.gov |
| I-SCREEN: Increasing Screening for Cancer using a Randomized Evaluation of EHR-based Nudges | NIH | National Institute on Aging | 2021 | $294,241 | August 15, 2020 | July 31, 2022 | NAVATHE, AMOL S | reporter.nih.gov |
| Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and Liver Cancer (CLOVER) | NIH | National Institute on Aging | 2021 | $293,756 | August 15, 2020 | July 31, 2022 | CHAK, ERIC W | reporter.nih.gov |
| Targeting regenerative reprogramming in colorectal cancer | NIH | National Cancer Institute | 2023 | $292,597 | September 1, 2023 | June 30, 2024 | ALONSO MARTINEZ, SALVADOR | reporter.nih.gov |
| A Novel Bacterially-derived Product to Enhance Immunity and Response to Immune Checkpoint Therapy | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $289,194 | May 6, 2022 | April 30, 2024 | KOH, ANDREW | reporter.nih.gov |
| Dietary Regulation of Colon Cancer Metastasis | NIH | National Cancer Institute | 2021 to 2023 | $283,042 | May 1, 2021 | January 18, 2024 | GOSWAMI, SWAGATA | reporter.nih.gov |
| Improving Cancer Screening Through A Tailored Technology-Based Intervention | NIH | National Institute on Aging | 2021 | $283,016 | August 15, 2020 | July 31, 2022 | DIAZ, VANESSA ASTRUD | reporter.nih.gov |
| Targeting casein kinase 1-alpha for cancer therapy | NIH | National Cancer Institute | 2021 to 2022 | $282,603 | July 6, 2018 | June 30, 2024 | CORSELLO, STEVEN MUNTEAN | reporter.nih.gov |
| Investigation of the Carcinogenic Effects of Bactericidal Antibiotics in the Gut | NIH | National Cancer Institute | 2021 to 2023 | $278,201 | February 1, 2021 | March 14, 2023 | SHIN, WOOJUNG | reporter.nih.gov |
| Nuclear Transport of Extracellular Vesicle Biomaterials | NIH | National Cancer Institute | 2021 | $275,000 | August 1, 2021 | July 31, 2024 | LORICO, AURELIO | reporter.nih.gov |
| EPICERTIN for Mucosal Healing in Ulcerative Colitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 | $273,556 | September 19, 2022 | August 31, 2024 | TUSE, DANIEL | reporter.nih.gov |
| Improving the safety and effectiveness of adhesion prevention following colorectal procedures with high risk of cancer or infection | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 | $269,911 | September 30, 2022 | August 31, 2024 | KEANE, TIMOTHY JOSEPH | reporter.nih.gov |
| SESORRS endoscopy for the staging and evaluation of colorectal cancer | NIH | National Cancer Institute | 2022 to 2023 | $266,978 | June 8, 2022 | December 31, 2023 | NICOLSON, FAY | reporter.nih.gov |
| The Effects of Insurance Benefit Design Innovation on Patient Health | NIH | National Institute on Aging | 2021 to 2023 | $259,455 | March 15, 2019 | August 15, 2023 | WHALEY, CHRISTOPHER | reporter.nih.gov |
| Dye-free, multimodal, quantitative imaging to assess bowel perfusion during laparoscopic colorectal resection | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $256,579 | September 1, 2021 | August 31, 2023 | CHA, RICHARD JAEPYEONG | reporter.nih.gov |
| Low Cost Spectroscopic OCT for GI Applications | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 | $256,323 | September 20, 2021 | December 19, 2022 | BROWN, WILLIAM | reporter.nih.gov |
| Molecular Mechanisms Underlying Environmental Effects that Influence Penetrance in Lynch Syndrome-Associated Endometrial Cancer | NIH | National Cancer Institute | 2021 | $256,000 | April 5, 2017 | February 28, 2024 | YATES, MELINDA S. | reporter.nih.gov |
| Optimizing Thermal Ablation for Colon Cancer Liver Metastases: Rapid Tissue Analysis Allowing for Immediate Retreatment; Metabolic Imaging Biomarker Validation; and Predictive Genetic Signatures | NIH | National Cancer Institute | 2022 | $251,889 | September 12, 2019 | February 29, 2024 | SOFOCLEOUS, CONSTANTINOS THASOS | reporter.nih.gov |
| Impact of sugary drinks on gut microbiota and development of young-onset colorectal cancer | NIH | National Cancer Institute | 2021 | $251,400 | June 1, 2021 | August 31, 2022 | YUN, JIHYE | reporter.nih.gov |
| Inflammation, Physical Activity, and Colon Cancer Recurrence and Survival | NIH | National Cancer Institute | 2021 | $249,000 | April 3, 2019 | March 31, 2024 | BROWN, JUSTIN C | reporter.nih.gov |
| The effects of Ojeok-san on neuro-immune interactions in cancer-induced visceral pain | NIH | National Center for Complementary & Integrative Health | 2021 | $249,000 | September 1, 2019 | August 31, 2023 | VELAZQUEZ, KANDY T | reporter.nih.gov |
| Optimizing Colorectal Cancer Screening among Patients with Diabetes in Safety-Net Primary Care Settings: Targeting Implementation Approaches | NIH | National Cancer Institute | 2022 | $249,000 | January 1, 2021 | May 31, 2023 | O'MALLEY, DENALEE M. | reporter.nih.gov |
| Early prediction of colorectal liver metastases treatment response with ultrasound microvessel imaging | NIH | National Cancer Institute | 2021 | $248,964 | March 1, 2017 | January 31, 2023 | SONG, PENGFEI | reporter.nih.gov |
| American Samoa Indigenous Samoan Partnership to Initiate REsearch Excellence (INSPIRE) in Colorectal Cancer Health Literacy | NIH | National Institute on Minority Health and Health Disparities | 2021 | $246,550 | July 1, 2016 | January 31, 2023 | TOFAEONO, VAATAUSILI T | reporter.nih.gov |
| Inferring the roots of metastases and their effects on patient survival | NIH | National Cancer Institute | 2021 | $245,022 | July 1, 2018 | August 28, 2022 | REITER, JOHANNES G | reporter.nih.gov |
| Dissecting roles of microbiome-host interactions in colorectal neoplasia etiology using multi-omics data | NIH | National Cancer Institute | 2021 to 2022 | $242,406 | January 5, 2021 | December 31, 2022 | YANG, YAOHUA | reporter.nih.gov |
| Influence of Dietary Pattern and Race on Metabolic and Epigenetic Alterations Associated with Cancer Development | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2022 | $240,748 | September 25, 2020 | April 30, 2024 | MILES, FAYTH | reporter.nih.gov |
| Overcoming barriers to cancer screening among women living in rural and segregated communities | NIH | National Cancer Institute | 2021 to 2022 | $239,476 | September 1, 2019 | August 31, 2023 | MOSS, JENNIFER LINDSAY | reporter.nih.gov |
| Defining host-microbiota interactions during colorectal cancer and immune checkpoint blockade | NIH | National Cancer Institute | 2021 | $237,724 | April 1, 2020 | March 31, 2023 | SONNENBERG, GREGORY F | reporter.nih.gov |
| Targeting the IL-33/ST2 Pathway in Colorectal Cancer Immunotherapy | NIH | National Cancer Institute | 2021 to 2022 | $237,442 | April 1, 2021 | September 30, 2022 | VAN DER JEUGHT, KEVIN | reporter.nih.gov |
| Optimal early colorectal cancer screening initiation | NIH | National Cancer Institute | 2022 to 2023 | $233,896 | September 1, 2022 | December 31, 2024 | DEMB, JOSHUA BRIAN | reporter.nih.gov |
| Tumor-specific activation of transgene expression by Scd3 locus | NIH | National Cancer Institute | 2021 | $230,010 | December 11, 2019 | November 30, 2023 | NAKANISHI, MASAKO | reporter.nih.gov |
| Reducing serine biosynthesis and utilization as a novel approach for colon cancer prevention | NIH | National Cancer Institute | 2021 | $229,478 | February 1, 2019 | January 31, 2022 | MONTROSE, DAVID C | reporter.nih.gov |
| Delineating the mechanisms by which tumor immunity multicellular networks shape T cell state | NIH | National Cancer Institute | 2023 | $226,554 | August 23, 2023 | June 30, 2024 | CHEN, JONATHAN HOWARD | reporter.nih.gov |
| Statistical Methods for Analysis of Tumor Heterogeneity in Genetic Epidemiology | NIH | National Cancer Institute | 2021 | $218,775 | July 1, 2015 | March 31, 2022 | HSU, LI | reporter.nih.gov |
| APC + TP53 Combinatorial Mutations Emerging as Biomarkers to Predict EGFRI Sensitivity | NIH | National Cancer Institute | 2021 | $213,881 | August 1, 2021 | April 16, 2022 | YEATMAN, TIMOTHY J | reporter.nih.gov |
| Leveraging Implementation Science to Promote Behavior Change and Reduce Cancer Health Disparities among American Indian and Alaska Native Older Adults | NIH | National Cancer Institute | 2021 to 2023 | $206,400 | May 4, 2021 | August 31, 2023 | PEDERSEN, MAJA | reporter.nih.gov |
| Investigating cancer metabolism and its potential for therapeutic intervention | NIH | National Cancer Institute | 2021 to 2022 | $204,317 | July 23, 2019 | December 23, 2022 | MONTAL, EMILY DINA | reporter.nih.gov |
| The role of Fusobacterium in colorectal cancer treatment, tumor ecology and chemotherapeutic efficacy | NIH | National Cancer Institute | 2021 | $204,273 | August 1, 2019 | March 31, 2022 | BULLMAN, SUSAN | reporter.nih.gov |
| A Metabolic Engineering Strategy to Map Sialyltransferase Glycosites | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $202,284 | July 26, 2021 | July 25, 2024 | TILL, NICHOLAS ALEXANDER | reporter.nih.gov |
| Defining an immunological mechanism for a microbiota-based therapy for colorectal cancer | NIH | National Cancer Institute | 2021 | $200,410 | March 6, 2020 | February 28, 2022 | HAND, TIMOTHY WESLEY | reporter.nih.gov |
| Use of simulation-based mastery learning to improve polypectomy outcomes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $198,958 | June 1, 2020 | March 31, 2024 | BARSUK, JEFFREY H | reporter.nih.gov |
| Alcohol, Gut Dysbiosis, Endotoxemia, and Colorectal Cancer | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 | $195,270 | February 20, 2020 | January 31, 2023 | CAO, YIN | reporter.nih.gov |
| Defining the relationship between kinase inhibitor pharmacophores and pro-/anti-targets using in vivo models of colorectal cancer | NIH | National Cancer Institute | 2021 to 2022 | $195,178 | February 15, 2019 | April 29, 2022 | MARSIGLIA, WILLIAM M | reporter.nih.gov |
| Targeting macrophages to reduce colorectal cancer: Impact of metabolic reprogramming | NIH | National Cancer Institute | 2021 to 2022 | $193,112 | September 14, 2018 | August 31, 2023 | BADER, JACKIE | reporter.nih.gov |
| High-Throughput Functional Genomics to Guide Precision Oncology in Gastrointestinal Tumors | NIH | National Cancer Institute | 2021 | $192,240 | January 1, 2019 | December 31, 2021 | SHEN, JOHN PAUL YING CHING | reporter.nih.gov |
| Colon cancer prevention with non-systemic PDE5 inhibitors | NIH | National Cancer Institute | 2022 | $191,738 | August 1, 2022 | July 31, 2024 | BROWNING, DARREN D. | reporter.nih.gov |
| Saturation genome editing approach to functionally test all possible MSH2 variants | NIH | National Cancer Institute | 2021 | $191,675 | December 12, 2019 | November 30, 2023 | HEINEN, CHRISTOPHER D. | reporter.nih.gov |
| Comprehensive identification of RAS mutations and allelic co-segregation patterns in colorectal cancer | NIH | National Cancer Institute | 2021 to 2022 | $187,000 | December 14, 2020 | November 30, 2023 | SEREBRIISKII, ILYA | reporter.nih.gov |
| Determinants of Repeat Colorectal Cancer Screening in a Safety-Net System | NIH | National Cancer Institute | 2022 to 2023 | $180,582 | July 1, 2022 | June 30, 2025 | NONZEE, NARISSA JENNIFER | reporter.nih.gov |
| The role of DCLK1 in the initiation of pancreatic ductal adenocarcinoma and colorectal cancer | NIH | National Cancer Institute | 2021 to 2022 | $179,310 | September 19, 2018 | August 31, 2023 | QU, DONGFENG | reporter.nih.gov |
| Developing a Barbershop-Based Trial on Masculinity Barriers to Care and Colorectal Cancer Screening Uptake among African-American Men using a Mixed Methods Approach | NIH | National Cancer Institute | 2021 | $175,673 | September 17, 2018 | May 20, 2022 | ROGERS, CHARLES R. | reporter.nih.gov |
| Developing a Barbershop-Based Trial on Masculinity Barriers to Care and Colorectal Cancer Screening Uptake among African-American Men using a MixedMethods Approach | NIH | National Cancer Institute | 2022 | $175,673 | September 17, 2018 | August 31, 2024 | ROGERS, CHARLES R. | reporter.nih.gov |
| NCI PATTERNS OF CARE STUDIES FOR DIAGNOSIS YEAR 2020 BREAST CANCER AND COLORECTAL CANCER CASES | NIH | National Cancer Institute | 2023 | $173,602 | December 23, 2022 | December 22, 2023 | DURBIN, ERIC | reporter.nih.gov |
| Development of a noninvasive, rapid and affordable method for early detection of colorectal cancer | NIH | National Cancer Institute | 2021 to 2022 | $172,029 | July 1, 2020 | June 30, 2025 | OSKERITZIAN, CAROLE A | reporter.nih.gov |
| APC + TP53 Combinatorial Mutations Emerging as Biomarkers to Predict EGFRI Sensitivity | NIH | National Cancer Institute | 2022 | $171,233 | April 16, 2022 | July 31, 2024 | YEATMAN, TIMOTHY J | reporter.nih.gov |
| Targeting ERK5 for Colorectal Cancer Therapy | NIH | National Cancer Institute | 2021 | $169,469 | May 13, 2020 | August 31, 2022 | POWIS, GARTH | reporter.nih.gov |
| Cancer Emulation Analysis with Deep Neural Network | NIH | National Cancer Institute | 2023 | $167,500 | September 19, 2023 | August 31, 2025 | MA, SHUANGGE | reporter.nih.gov |
| Targeting Wnt-dependent colorectal cancer | NIH | National Cancer Institute | 2021 | $166,963 | March 1, 2018 | May 31, 2021 | ROBBINS, DAVID J | reporter.nih.gov |
| Delineating the Role of KAP1 in WNT-induced Colorectal Cancer | NIH | National Cancer Institute | 2022 to 2023 | $164,000 | January 1, 2022 | December 31, 2023 | D'ORSO, IVAN | reporter.nih.gov |
| A personalized colorectal cancer-on-a-chip for assessing tumor-microbiome crosstalk | NIH | National Cancer Institute | 2021 | $162,759 | May 1, 2019 | August 31, 2022 | KIM, HYUN JUNG | reporter.nih.gov |
| Measuring Gender in the Healthy Oregon Project | NIH | National Cancer Institute | 2023 | $161,578 | September 13, 2023 | May 31, 2025 | SHANNON, JACKILEN | reporter.nih.gov |
| Gene Dependent Cancer Risk and Optimal Cancer Prevention Strategies in Lynch Syndrome | NIH | National Cancer Institute | 2021 | $158,516 | April 11, 2018 | September 30, 2022 | SHARAF, RAVI | reporter.nih.gov |
| Identifying the active factor of an anti-inflammatory chemopreventive bacterium | NIH | National Cancer Institute | 2021 | $157,235 | May 1, 2021 | February 5, 2022 | CROTT, JIMMY W | reporter.nih.gov |
| Role of a Two-Factor Genetic Circuit Regulating Stemness in Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2023 | $155,482 | June 1, 2021 | October 31, 2025 | HU, SOFIA | reporter.nih.gov |
| Infertility and Risk of Breast, Gynecologic, and Colorectal Cancer | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $153,500 | April 1, 2021 | March 31, 2024 | FARLAND, LESLIE V | reporter.nih.gov |
| Fatty acid synthase in regulation of UDP-GlcNAc synthesis in colorectal cancer | NIH | National Cancer Institute | 2021 to 2022 | $153,000 | July 1, 2021 | June 30, 2023 | ZAYTSEVA, YEKATERINA | reporter.nih.gov |
| Alterations in DNA Damage following Major Surgery and Hyperthermic Intraperitoneal Chemotherapy | NIH | National Cancer Institute | 2022 to 2023 | $152,670 | August 5, 2022 | July 31, 2024 | KIM, JOSEPH | reporter.nih.gov |
| Colorectal tumorigenesis on a cricket powder-based diet versus diets based on more typical protein sources | NIH | National Cancer Institute | 2021 to 2022 | $151,000 | March 8, 2021 | August 31, 2023 | MASON, JOEL B | reporter.nih.gov |
| Global metabolomics profiling, dietary factors, and colorectal cancer risk in the NIH-Consortium of Metabolomics Studies (COMETS) | NIH | National Cancer Institute | 2022 to 2023 | $150,975 | June 14, 2022 | May 31, 2025 | PLAYDON, MARY CHRISTINE | reporter.nih.gov |
| Exploring the impact of HSP90 inhibition on antigen presentation and anti-tumor immune responses | NIH | National Cancer Institute | 2021 | $150,223 | March 2, 2020 | February 28, 2022 | JAEGER, ALEX | reporter.nih.gov |
| Statistical methods for cancer progression delineation and subtype identification | NIH | National Cancer Institute | 2021 to 2022 | $149,804 | July 1, 2021 | June 30, 2024 | WANG, CHI | reporter.nih.gov |
| Translational Epigenomics in Gastrointestinal Cancer | NIH | National Cancer Institute | 2021 | $147,343 | September 19, 2018 | March 31, 2022 | YU, MING | reporter.nih.gov |
| Malignant Cell Engagement in Immune Circuits of Human Microsatellite-stable and Microsatellite-instable Colorectal Cancer | NIH | National Cancer Institute | 2021 | $137,295 | April 8, 2021 | August 31, 2021 | PELKA, KARIN | reporter.nih.gov |
| The Functional Role of GRM3 in Colon Cancer | NIH | National Cancer Institute | 2021 | $135,998 | August 15, 2020 | June 21, 2022 | GENG, LIYING | reporter.nih.gov |
| AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia | NIH | National Cancer Institute | 2021 | $134,809 | September 25, 2017 | August 31, 2022 | RODGERS, BUEL | reporter.nih.gov |
| Developing an intervention to improve follow-up of abnormal fecal immunochemical test results in a safety-net population using a mixed methods approach | NIH | National Cancer Institute | 2021 | $134,048 | September 1, 2019 | March 31, 2022 | ISSAKA, RACHEL B. | reporter.nih.gov |
| Elucidating Molecular Mechanisms of Cancer Development by Investigating Key DNA Repair Pathways | NIH | National Cancer Institute | 2021 | $131,595 | September 1, 2020 | August 31, 2023 | LEBLANC, SHARONDA | reporter.nih.gov |
| Targeting casein kinase 1-alpha for cancer therapy | NIH | National Cancer Institute | 2021 | $130,475 | July 6, 2018 | February 28, 2022 | CORSELLO, STEVEN MUNTEAN | reporter.nih.gov |
| Investigating the Role of IL-23R in Mucosal Regulatory T Cells | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $129,750 | July 10, 2020 | April 30, 2022 | GOETTEL, JEREMY ALLEN | reporter.nih.gov |
| Risk-stratified self-management care for colorectal cancer survivors: a new approach to increasing adherence to health behavior recommendations | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 | $129,507 | August 1, 2023 | July 31, 2024 | SLEIGHT, ALIX G. | reporter.nih.gov |
| Shared decision-making and colorectal cancer screening behaviors among older adults with low health literacy | NIH | National Institute on Aging | 2021 | $126,484 | January 15, 2020 | December 31, 2021 | CADET, TAMARA J. | reporter.nih.gov |
| Investigating a Wnt-telomere feedback loop in the colorectal adenoma-carcinoma sequence | NIH | National Cancer Institute | 2021 to 2023 | $122,674 | March 1, 2021 | August 4, 2023 | ESTEP, KATRINA NOEL | reporter.nih.gov |
| Elucidating the Role of SMAD4 in Colorectal Cancer | NIH | National Cancer Institute | 2021 | $120,264 | May 1, 2020 | April 30, 2022 | TONG, KEVIN | reporter.nih.gov |
| An Engineered Nanocarrier Platform for Enhancing Immune Responses to Neoantigen-Targeted Cancer Vaccines | NIH | National Cancer Institute | 2021 to 2023 | $119,772 | January 13, 2021 | May 13, 2023 | BALJON, JESSALYN J | reporter.nih.gov |
| Advanced genetic systems for Fusobacterium nucleatum in oral and extra-oral pathologies | NIH | National Institute of Dental & Craniofacial Research | 2023 | $119,645 | September 19, 2023 | May 1, 2024 | JOHNSTON, CHRISTOPHER D | reporter.nih.gov |
| Diet and the colonic exfoliome: a novel, non-invasive approach to testing interventions in humans | NIH | National Cancer Institute | 2021 | $119,129 | January 1, 2020 | March 31, 2022 | LAMPE, JOHANNA W | reporter.nih.gov |
| Genetics of Tumor Suppression by p53 | NIH | National Cancer Institute | 2021 | $119,031 | March 4, 2020 | December 1, 2021 | BARNOUD, THIBAUT | reporter.nih.gov |
| Deciphering the mechanism of colibactin-induced DNA damage through quantitative and biochemical approaches | NIH | National Cancer Institute | 2021 to 2022 | $114,015 | July 6, 2020 | February 17, 2023 | CARLSON, ERIK S | reporter.nih.gov |
| The Social Environment and Colorectal Cancer in the United States | NIH | National Cancer Institute | 2021 to 2023 | $112,964 | September 1, 2021 | June 30, 2024 | SANTIAGO-RODRIGUEZ, EDUARDO JOSE | reporter.nih.gov |
| NCI PATTERNS OF CARE STUDY: (DIAGNOSIS YEAR 2020 BREAST CANCER AND COLORECTAL CANCER) | NIH | National Cancer Institute | 2023 | $109,264 | December 23, 2022 | December 22, 2023 | SCHWARTZ, PHD, STEPHEN | reporter.nih.gov |
| Optimizing the Impact of Aspirin for Chemoprevention | NIH | National Cancer Institute | 2021 | $108,708 | July 6, 2018 | September 30, 2022 | CAO, YIN | reporter.nih.gov |
| EFFECT OF WESTERN DIET IN GASTROINTESTINAL CANCER BY NMR METABOLOMICS | NIH | National Institute of General Medical Sciences | 2021 | $105,000 | July 1, 2018 | June 30, 2024 | KRISHNAN, VISWANATHAN V | reporter.nih.gov |
| Adaptive immunity in primary sclerosing cholangitis patients at risk for colorectal cancer | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $102,788 | July 1, 2019 | June 30, 2023 | SHAW, DUSTIN | reporter.nih.gov |
| Developing multiplexed microenvironmental sensors for precision diagnostics of cancer metastasis | NIH | National Cancer Institute | 2021 | $101,334 | December 1, 2019 | November 30, 2022 | HAO, LIANGLIANG | reporter.nih.gov |
| Colonoscopy in young onset colorectal cancer | NIH | National Cancer Institute | 2021 to 2022 | $101,291 | March 1, 2022 | August 31, 2022 | DEMB, JOSHUA BRIAN | reporter.nih.gov |
| Functional analyses of super-enhancer dysregulation in colorectal carcinoma patient samples. | NIH | National Cancer Institute | 2021 to 2022 | $101,064 | July 1, 2019 | June 5, 2023 | ZHOU, ROYCE | reporter.nih.gov |
| PATTERNS OF CARE STUDY: DIAGNOSIS YEAR 2020 (BREAST CANCER AND COLORECTAL CANCER) | NIH | National Cancer Institute | 2023 | $97,457 | December 23, 2022 | December 22, 2023 | GONSALVES, LOU | reporter.nih.gov |
| The Role of Klotho Beta in Colorectal Cancer Tumorigenesis | NIH | National Cancer Institute | 2021 to 2023 | $97,150 | January 4, 2021 | January 3, 2024 | ROHR, MICHAEL W | reporter.nih.gov |
| The role of unacylated ghrelin on age-associated progressive muscle weakness and cachexia elicited by cancer | NIH | National Institute on Aging | 2021 | $95,979 | February 15, 2020 | January 31, 2022 | AHN, BUMSOO | reporter.nih.gov |
| Restoring Guanylin-Guanylate cyclase C Signaling to Prevent Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2022 | $95,324 | January 1, 2019 | December 31, 2022 | RAPPAPORT, JEFFREY | reporter.nih.gov |
| Ferroptosis as a Modulator of Checkpoint Inhibitor Immunotherapy | NIH | National Cancer Institute | 2021 to 2023 | $94,531 | April 1, 2021 | March 31, 2024 | TALTY, RONAN CHRISTOPHER | reporter.nih.gov |
| Molecular mechanisms of Trypanosoma cruzi induced colon pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $94,446 | December 9, 2021 | December 8, 2023 | RAYFORD, KAYLA | reporter.nih.gov |
| Dissecting mechanisms of inflammation driven cancer susceptibility in epithelial barrier tissues | NIH | National Cancer Institute | 2021 to 2022 | $94,288 | September 1, 2021 | August 31, 2023 | COWLEY, CHRISTOPHER | reporter.nih.gov |
| Bacterial Rogue Methyltransferases Inducing Human Epimutations | NIH | National Cancer Institute | 2021 to 2022 | $91,888 | June 1, 2021 | August 31, 2022 | FINK, EMILY E | reporter.nih.gov |
| PATTERNS OF CARE STUDY -DIAGNOSIS YEAR 2020 BREAST CANCER AND COLORECTAL CANCER | NIH | National Cancer Institute | 2023 | $90,751 | December 23, 2022 | December 22, 2023 | MANISCALCO, LAUREN | reporter.nih.gov |
| Cell type and molecular determinants of colorectal cancer initiation downstream of APC inactivation | NIH | National Cancer Institute | 2021 | $89,314 | September 19, 2017 | August 31, 2022 | LI, NING | reporter.nih.gov |
| NCI PATTERNS OF CARE STUDIES FOR DIAGNOSIS YEAR 2020 BREAST CANCER AND COLORECTAL CANCER CASES | NIH | National Cancer Institute | 2023 | $88,805 | December 23, 2022 | December 22, 2023 | STROUP, ANTOINETTE | reporter.nih.gov |
| Discovery and Mechanistic Characterization of New Cytotoxic Agents from Marine Cyanobacteria | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $88,646 | August 16, 2021 | August 15, 2023 | ELSADEK, LOBNA | reporter.nih.gov |
| PATTERNS OF CARE (POC) STUDY: DIAGNOSIS YEAR 2020 (BREAST CANCER AND COLORECTAL CANCER) | NIH | National Cancer Institute | 2023 | $87,431 | December 23, 2022 | December 22, 2023 | WIGGINS, CHARLES | reporter.nih.gov |
| Elucidating the impact of DNA hypomethylation on genome organization and anti-tumor transcriptional programs. | NIH | National Cancer Institute | 2021 | $87,051 | April 1, 2021 | August 31, 2021 | JOHNSTONE, SARAH E | reporter.nih.gov |
| Optimizing Gram-positive bacteria as a candidate for targeted anti-tumor therapy | NIH | National Cancer Institute | 2021 to 2022 | $86,115 | July 1, 2020 | December 1, 2022 | SHUSTER, BENTLEY M. | reporter.nih.gov |
| Function of IRF8 in T cell activation and immune tolerance | NIH | National Cancer Institute | 2021 to 2022 | $84,901 | December 18, 2018 | May 13, 2022 | KLEMENT, JOHN DAVID | reporter.nih.gov |
| Functions of KAT2A and KAT2B in intestinal homeostasis and colon cancer. | NIH | National Cancer Institute | 2021 to 2022 | $84,768 | September 1, 2020 | August 31, 2023 | NGUYEN, MAI UYEN | reporter.nih.gov |
| Exploring the Role of Drp1 in Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2023 | $84,752 | April 1, 2021 | July 25, 2023 | HASANI, SUMATI RAJ | reporter.nih.gov |
| Investigating the role of EZH2 as a therapeutic target in colorectal cancers | NIH | National Cancer Institute | 2021 to 2023 | $84,628 | April 1, 2021 | May 31, 2023 | LOI, PATRICK | reporter.nih.gov |
| Biomarkers of Inflammation, Vitamin D, and Colorectal Cancer Risk and Survival | NIH | National Cancer Institute | 2021 to 2022 | $84,329 | January 3, 2019 | June 28, 2022 | GIBBS, DAVID CORLEY | reporter.nih.gov |
| Oncogenic Kras drives stromal adipogenesis to promote colorectal cancer (CRC) progression | NIH | National Cancer Institute | 2022 to 2023 | $83,670 | August 1, 2022 | November 8, 2023 | HSU, WEN-HAO | reporter.nih.gov |
| Integrative Approach to Understand the Role of Diet, Physical Activity and Adiposity on Survival in Patients with Colorectal, Endometrial and Prostate Cancer | NIH | National Cancer Institute | 2021 | $82,818 | May 15, 2020 | April 30, 2022 | LEE, DONGHOON | reporter.nih.gov |
| Missorting of EGFR in cancer pathogenesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $81,875 | March 10, 2020 | February 28, 2022 | SINGLA, AMIKA | reporter.nih.gov |
| Sensitizing Colorectal Cancer to Checkpoint Inhibitors by WNT Pathway Suppression | NIH | National Cancer Institute | 2021 to 2022 | $81,540 | January 1, 2020 | August 2, 2022 | KATTI, ALYNA | reporter.nih.gov |
| Engineering injectable T cell stimulating microparticles for cancer immunotherapy | NIH | National Cancer Institute | 2022 to 2023 | $81,027 | September 1, 2022 | March 8, 2024 | LIVINGSTON, NATALIE KATERINA | reporter.nih.gov |
| Epigenetic regulation of myeloid regulatory cell accumulation in the tumor microenvironment | NIH | National Cancer Institute | 2021 to 2022 | $80,603 | December 18, 2020 | June 30, 2022 | MERTING, ALYSSA | reporter.nih.gov |
| Defining the function of SETD8 in colorectal cancer | NIH | National Cancer Institute | 2021 to 2022 | $80,215 | March 1, 2020 | February 28, 2023 | CRAMER, ZVI | reporter.nih.gov |
| ω-3 fatty acid-derived mediators promote resolution of inflammation: Uncovering new strategies for preventing colitis-associated colon cancer | NIH | National Cancer Institute | 2021 | $80,000 | February 10, 2020 | January 31, 2023 | ZUO, XIANGSHENG | reporter.nih.gov |
| WDR5 WIN Site Inhibition in Colorectal Cancer | NIH | National Cancer Institute | 2022 | $79,988 | July 1, 2022 | June 30, 2023 | GRIEB, BRIAN C | reporter.nih.gov |
| NCI PATTERNS OF CARE STUDY: DIAGNOSIS YEAR (2020 BREAST CANCER AND COLORECTAL CANCER) | NIH | National Cancer Institute | 2023 | $79,740 | December 23, 2022 | December 22, 2023 | DOHERTY, JENNIFER | reporter.nih.gov |
| Characterization of the PKM2-RAS Interaction as a Novel Metabolic Vulnerability of RAS-driven Tumors | NIH | National Cancer Institute | 2021 to 2022 | $76,330 | April 1, 2021 | March 31, 2023 | KOCHEN ROSSI, JUAN ANDRES | reporter.nih.gov |
| Identification of a central player in neoplastic transformation of intestinal stem cells:protocadherin 8 | NIH | National Cancer Institute | 2021 | $76,000 | December 10, 2019 | November 30, 2022 | VAN LANDEGHEM, LAURIANNE CHANTAL | reporter.nih.gov |
| NCI PATTERNS OF CARE STUDY: DIAGNOSIS YEAR (2020 BREAST CANCER AND COLORECTAL CANCER) | NIH | National Cancer Institute | 2023 | $75,887 | December 23, 2022 | December 22, 2023 | WEST, MICHELE | reporter.nih.gov |
| Microbiota metabolites SCFA promote intestinal epithelial repair and wound healing | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $72,468 | March 1, 2019 | February 28, 2023 | BILOTTA, ANTHONY J | reporter.nih.gov |
| NCI PATTERNS OF CARE STUDY - DIAGNOSIS YEAR 2020 BREAST CANCER AND COLORECTAL CANCER | NIH | National Cancer Institute | 2023 | $71,719 | December 23, 2022 | December 22, 2023 | HERNANDEZ, BRENDA | reporter.nih.gov |
| Exploiting Oncogenic Chromatin Regulators in Cancer Initiation and Progression | NIH | National Cancer Institute | 2021 to 2022 | $71,638 | September 1, 2021 | August 31, 2023 | HYDER, USMAN | reporter.nih.gov |
| Immune-regulating MHC class I-like proteins and colorectal cancer risk | NIH | National Cancer Institute | 2021 | $71,244 | March 1, 2020 | August 31, 2022 | PRIZMENT, ANNA | reporter.nih.gov |
| Small-molecule Inhibition of Glycogen Synthase Kinase-3 Sensitizes Colorectal Cancer Cells and Stimulates Immune Cells to Bolster Immune Cell-mediated Tumor Cytotoxicity | NIH | National Cancer Institute | 2022 to 2023 | $70,682 | March 15, 2022 | May 31, 2023 | HUNTINGTON, KELSEY ELIZABETH | reporter.nih.gov |
| Determining how the human gut microbiota modulates colon cancer tumorigenesis | NIH | National Cancer Institute | 2021 | $70,458 | September 1, 2019 | August 31, 2022 | WEIS, ALLISON | reporter.nih.gov |
| Detection of Colorectal Cancer Adaptive Mutability May Justify Combination of Targeted- and Immune-Therapies | NIH | National Cancer Institute | 2021 | $68,770 | September 20, 2021 | April 16, 2022 | YEATMAN, TIMOTHY J | reporter.nih.gov |
| Defining the contributions of WT RAS in RAS-mutant lung cancer | NIH | National Cancer Institute | 2021 | $68,562 | January 2, 2019 | January 1, 2022 | STALNECKER, CLINT A | reporter.nih.gov |
| Leveraging Metalloinsertors for the PET Imaging and Endoradiotherapy of MMR-Deficient Cancers | NIH | National Cancer Institute | 2022 to 2023 | $65,410 | August 15, 2022 | August 14, 2024 | DELANEY, SAMANTHA PATRICIA | reporter.nih.gov |
| Top-down proteomic characterization of MEK/ERK in MAPK-driven cancers | NIH | National Cancer Institute | 2021 | $63,738 | September 1, 2020 | August 14, 2022 | DROWN, BRYON SHANE | reporter.nih.gov |
| Systems Approach to Dynamic Interplay between cAMP/PKA and ERK Signaling | NIH | National Cancer Institute | 2022 to 2023 | $62,682 | March 1, 2022 | July 31, 2023 | POSNER, CLARA ANNE | reporter.nih.gov |
| Small molecule inhibitors for the study of colibactin-induced carcinogenesis by gut microbes | NIH | National Cancer Institute | 2021 to 2022 | $62,196 | February 1, 2020 | June 10, 2022 | VOLPE, MATTHEW ROBERT | reporter.nih.gov |
| Defining the Boundaries of RNAi in a cell | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $60,788 | May 11, 2020 | May 10, 2023 | JOHNSON, KRYSTAL COURTNEY | reporter.nih.gov |
| Development of Novel Herbal Therapy for Prevention of Irinotecan-induced Severe Delayed Onset Diarrhea | NIH | National Center for Complementary & Integrative Health | 2021 | $52,000 | September 21, 2020 | September 20, 2022 | SINGH, RASHIM | reporter.nih.gov |
| CLEAN: A community-engaged intervention to increase colorectal cancer screening in Chinese American immigrants | NIH | National Cancer Institute | 2022 | $51,530 | September 14, 2022 | January 31, 2023 | VANG, SUZANNE SHARRY | reporter.nih.gov |
| Mechanisms of Transcriptional Regulation by MTG16 in the Intestine | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $51,036 | September 1, 2018 | April 30, 2023 | BROWN, RACHEL ELIZABETH | reporter.nih.gov |
| Engineered Fibroblasts as Cell Therapy to Treat Colorectal Cancer via Tumor Stroma Stabilization | NIH | National Cancer Institute | 2021 | $46,036 | August 1, 2020 | February 28, 2022 | JUNG, WEI-HUNG | reporter.nih.gov |
| Engineering tumor-targeting bacteria to sense and deliver therapeutics | NIH | National Cancer Institute | 2021 | $46,036 | August 10, 2020 | July 31, 2022 | HARIMOTO, TETSUHIRO | reporter.nih.gov |
| Quantifying heterocellular communication and spatial intratumoral heterogeneity from high dimensional spatial proteomics data | NIH | National Cancer Institute | 2021 | $45,520 | September 1, 2020 | August 31, 2022 | FURMAN, SAMANTHA A. | reporter.nih.gov |
| Combating Cetuximab Resistance in Colorectal Cancer | NIH | National Cancer Institute | 2021 | $43,397 | April 1, 2017 | March 31, 2022 | ZHANG, YUESHENG | reporter.nih.gov |
| Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Bind, Placebo-Controlled Phase II to Phase III Study | NIH | National Cancer Institute | 2021 | $42,581 | January 10, 2019 | May 31, 2021 | SMITH, ELLEN MARY LAVOIE | reporter.nih.gov |
| Effects of oxaliplatin-based chemotherapy on proprioception in cancer survivors | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $42,252 | September 1, 2020 | August 31, 2022 | WANG, ALLISON BINGQING | reporter.nih.gov |
| Genome-wide Patterns of DNA Damage and Repair in Resistance to Platinum-Based Chemotherapy | NIH | National Cancer Institute | 2021 | $41,629 | July 10, 2019 | May 31, 2022 | VAUGHN, COURTNEY MICHELLE | reporter.nih.gov |
| Defining the role of microenvironmental ammonia in colorectal cancers | NIH | National Cancer Institute | 2021 to 2022 | $40,225 | August 1, 2021 | August 2, 2022 | BELL, HANNAH NOELLE | reporter.nih.gov |
| ROLE OF SORD IN SUGAR-MEDIATED CANCER METASTASIS | NIH | National Cancer Institute | 2022 | $38,297 | March 8, 2022 | July 7, 2022 | YUN, JIHYE | reporter.nih.gov |
| Integrated Epidemiologic Study of Ultra-processed Foods and Colorectal Cancer Survival | NIH | National Cancer Institute | 2022 | $36,141 | August 1, 2022 | July 31, 2023 | DU, MENGXI | reporter.nih.gov |
| Inflammation Induced Cytosine Deamination and the Initiation of Cancer | NIH | National Cancer Institute | 2021 | $35,571 | July 1, 2018 | June 30, 2022 | HSU, CHIA WEI | reporter.nih.gov |
| Investigating the role of the mitochondrial pyruvate carrier in colon tumorigenesis | NIH | National Cancer Institute | 2021 | $31,138 | February 1, 2018 | May 22, 2021 | BENSARD, CLAIRE | reporter.nih.gov |
Organizations
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 4 | $12,086,314 | 0 | $0 |
| 2024 | 5 | $10,699,297 | 0 | $0 |
| 2023 | 162 | $64,145,218 | 0 | $0 |
| 2022 | 316 | $121,909,299 | 0 | $0 |
| 2021 | 410 | $165,050,844 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.